Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03056493 2019-09-13
WO 2018/172533 - 1 - PCT/EP2018/057482
T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST
PRAME POSITIVE CANCERS
The present invention pertains to antigen recognizing constructs against tumor
associated antigens (TAA), in particular against Preferentially Expressed
Antigen of
Melanoma (FRAME). The invention in particular provides novel T cell receptor
(TCR)
based molecules which are selective and specific for the tumor expressed
antigen of
the invention. The TCR of the invention, and TAA binding fragments derived
therefrom,
are of use for the diagnosis, treatment and prevention of TAA expressing
cancerous
diseases. Further provided are nucleic acids encoding the antigen recognizing
constructs of the invention, vectors comprising these nucleic acids,
recombinant cells
expressing the antigen recognizing constructs and pharmaceutical compositions
comprising the compounds of the invention.
DESCRI PTION
FRAME is encoded by the FRAME gene, which is expressed at a high level in a
large
proportion of tumors, including melanomas, non-small-cell lung carcinomas,
ovarian
carcinoma renal cell carcinoma (RCC), breast carcinoma, cervix carcinoma,
colon
carcinoma, sarcoma, neuroblastoma, as well as several types of leukemia. FRAME
is
the best characterized member of the FRAME family of leucine-rich repeat (LRR)
proteins. Mammalian genomes contain multiple members of the FRAME family
whereas in other vertebrate genomes only one FRAME-like LRR protein was
identified. FRAME is a cancer/testis antigen that is expressed at very low
levels in
normal adult tissues except testis but at high levels in a variety of cancer
cells.
T-cell based immunotherapy targets represent peptide epitopes derived from
tumor-
associated or tumor-specific proteins, which are presented by molecules of the
major
histocompatibility complex (MHC). These tumors associated antigens (TAAs) can
be
peptides derived from all protein classes, such as enzymes, receptors,
transcription
factors, etc. which are expressed and, as compared to unaltered cells of the
same
origin, usually up-regulated in cells of the respective tumor.
CA 03056493 2019-09-13
WO 2018/172533 - 2 - PCT/EP2018/057482
Specific elements of the cellular immune response are capable of specifically
recognizing and destroying tumor cells. The isolation of T-cells from tumor-
infiltrating
cell populations or from peripheral blood suggests that such cells play an
important role
in natural immune defense against cancer. CD8-positive T-cells in particular,
which
recognize class I molecules of the major histocompatibility complex (MHC)-
bearing
peptides of usually 8 to 10 amino acid residues derived from proteins or
defective
ribosomal products (DRiPs) located in the cytosol, play an important role in
this
response. The MHC-molecules of the human are also designated as human
leukocyte-
antigens (HLA).
There are two classes of MHC-molecules, MHC class I and MHC class II.
Complexes
of peptide and MHC class I are recognized by CD8-positive T-cells bearing the
appropriate T-cell receptor (TCR), whereas complexes of peptide and MHC class
ll
molecules are recognized by CD4- positive-helper-T-cells bearing the
appropriate
TCR. Since both types of response, CD8 and CD4 dependent, contribute jointly
and
synergistically to the anti-tumor effect, the identification and
characterization of tumor-
associated antigens and corresponding T cell receptors is important in the
development of cancer immunotherapies such as vaccines and cell therapies.
In the MHC class I dependent immune reaction, peptides not only have to be
able to
bind to certain MHC class I molecules expressed by tumor cells, they
subsequently
also have to be recognized by T-cells bearing specific T-cell receptors (TCR).
Therefore, TAAs are a starting point for the development of a T-cell based
therapy
including but not limited to tumor vaccines and cell therapies.
Approximately 90 percent of peripheral blood T cells express a TCR consisting
of an a
poly- peptide and a 8 polypeptide. A small percentage of T cells (about 5% of
total T
cells) have been shown to express a TCR consisting of a y polypeptide and a 6
polypeptide. yb T cells are found at their highest abundance in the gut
mucosa, within
a population of lymphocytes known as intraepithelial lymphocytes (IELs). The
antigenic
molecules that activate yb T cells are still widely unknown. However, yb T
cells are not
MHC restricted and seem to be able to recognize whole proteins rather than
requiring
peptides to be presented by MHC molecules on antigen presenting cells,
although
CA 03056493 2019-09-13
WO 2018/172533 - 3 - PCT/EP2018/057482
some recognize MHC class IB molecules. Human Vy9/V62 T cells, which constitute
the
major yb T cell population in peripheral blood, are unique in that they
specifically and
rapidly respond to a small non-peptidic microbial metabolite, HMB-PP, an
isopentenyl
pyrophosphate precursor. Estimates of the percentages of T cells that may be
found in
peripheral blood from healthy donors are as follows: CD3+.70.78 /0 4.71;
CD3+CD4+.38.97% 5.66; CD3+CD8+.28.955 /0 7.43; CD3+0D56+.5.22 /0 1.74;
CD3-CD56+=10.305% 4.7; CD3+CD45RA+=45.00`)/0 7.19;
and
CD3+CD45R0+.27.21% 7.34.
The chains of the T cell antigen receptor of a T cell clone are each composed
of a
unique combination of domains designated variable (V), [diversity (D),]
joining (J), and
constant (C). In each T cell clone, the combination of V, D and J domains of
both the
alpha and the beta chains or of both the delta and gamma chains participates
in
antigen recognition in a manner which is uniquely characteristic of that T
cell clone and
defines a unique binding site, also known as the idiotype of the T cell clone.
In contrast,
the C domain does not participate in antigen binding.
A TCR is a heterodimeric cell surface protein of the immunoglobulin super-
family,
which is associated with invariant proteins of the CD3 complex involved in
mediating
signal transduction. TCRs exist in a13 and yb forms, which are structurally
similar but
have quite distinct anatomical locations and probably functions. The
extracellular
portion of native heterodimeric ar3TCR and y6TCR each contain two
polypeptides,
each of which has a membrane-proximal constant domain, and a membrane-distal
variable domain. Each of the constant and variable domains include an intra-
chain
disulfide bond. The variable domains contain the highly polymorphic loops
analogous
to the complementarity determining regions (CDRs) of antibodies. The use of
TCR
gene therapy overcomes a number of current hurdles. It allows equipping
patients' own
T cells with desired specificities and generation of sufficient numbers of T
cells in a
short period of time, avoiding their exhaustion. The TCR will be transduced
into potent
T cells (e.g. central memory T cells or T cells with stem cell
characteristics), which may
ensure better persistence and function upon transfer. TCR-engineered T cells
will be
infused into cancer patients rendered lymphopenic by chemotherapy or
irradiation,
allowing efficient engraftment but inhibiting immune suppression.
CA 03056493 2019-09-13
WO 2018/172533 - 4 - PCT/EP2018/057482
While advances have been made in the development of molecular-targeting drugs
for
cancer therapy, there remains a need in the art to develop new anti-cancer
agents that
specifically target molecules highly specific to cancer cells. The present
description
addresses that need by providing novel FRAME TCRs, respective recombinant TCR
constructs, nucleic acids, vectors and host cells that specifically bind TAA
epitope(s) as
disclosed; and methods of using such molecules in the treatment of cancer. The
term
TAA in context of the invention relates in particular to the following
preferred proteins:
FRAME, and fragments or analogs thereof, in particular fragments or analogs
comprising or consisting of the antigenic peptide sequences shown in SEQ ID
NO: 97
to 115, preferably SEQ ID NO: 97 to 106, more preferably SEQ ID NO: 97.
The object of the invention is solved in a first aspect by an antigen
recognizing
construct comprising at least one complementary determining region (CDR) 3
having at
least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or preferably 100% sequence
identity to an amino acid sequence selected from SEQ ID Nos. 3, 9, 15, 21, 27,
33, 39,
45, 51, 57, 63, 69, 75, 81,129, and 135.
In some embodiments the antigen recognizing construct of the invention
specifically
binds to a TAA-peptide-HLA molecule complex, wherein the TAA peptide
comprises, or
alternatively consists of, a variant of the TAA which is at least 66%,
preferably at least
77%, and more preferably at least 88% homologous (preferably at least 77% or
at least
88% identical) to the amino acid sequence of the TAA of the invention, wherein
said
variant binds to an HLA class I or class ll molecule and/or induces T-cells
cross-
reacting with said peptide, or a pharmaceutically acceptable salt thereof,
wherein said
peptide is not the underlying full-length polypeptide.
As used herein, the terms "identical" or percent "identity", when used
anywhere herein
in the context of two or more nucleic acid or protein/polypeptide sequences,
refer to
two or more sequences or subsequences that are the same or have (or have at
least)
a specified percentage of amino acid residues or nucleotides that are the same
(i.e.,
at, or at least, about 60% identity, preferably at, or at least, 65%, 70%,
75%, 80%,
85%, 90%, 91%, 92%, 93% or 94%, identity, and more preferably at, or at least,
about
95%, 96%, 97%, 98%, 99%, or higher identity over a specified region -
preferably over
their full length sequences - , when compared and aligned for maximum
CA 03056493 2019-09-13
WO 2018/172533 - 5 - PCT/EP2018/057482
correspondence over the comparison window or designated region) as measured
using a sequence comparison algorithms, or by manual alignment and visual
inspection (see, e.g., NCBI web site). In a particular embodiment, for example
when
comparing the protein or nucleic acid sequence of an antigen recognizing
construct of
the invention to another protein/gene, the percentage identity can be
determined by the
Blast searches supported at the NCBI web site; in particular for amino acid
identity,
those using BLASTP with the following parameters: Expected threshold 10; Word
size:
6; Matrix: BLOSUM62; Gap Costs: Existence: 11, Extension: 1; Neighboring words
threshold: 11; Compositional adjustments: Conditional compositional score
matrix
adjustment.
In the context of the present invention it shall be understood that any
embodiments
referred to as "comprising" certain features of the invention, shall be
understood to
include in some more preferred embodiments the more restricted description of
"consisting of" or "consisting essentially of" the very same features of the
present
invention.
In another additional or alternative embodiment, the antigen recognizing
construct may
further comprise a CDR1 and/or a CDR2, or more preferably a CDR2bis, domain
sequence. Within the variable domain, CDR1 and CDR2 or CDR2bis, are found in
the
variable (V) region of a polypeptide chain, and CDR3 includes some of V, all
of
diversity (D) and joining (J) regions. CDR3 is the most variable and is the
main CDR
responsible for specifically and selectively recognizing an antigen. CDR1,
CDR2 and
CDR2bis sequences may be selected from a CDR sequence of a human variable
chain allele.
Native alpha-beta heterodimeric TCRs have an alpha chain and a beta chain.
Each
chain comprises variable, joining and constant regions, and the beta chain
also usually
contains a short diversity region between the variable and joining regions,
but this
diversity region is often considered as part of the joining region. Each
variable region
comprises three CDRs (Complementarity Determining Regions) embedded in a
framework sequence, one being the hypervariable region named CDR3. There are
several types of alpha chain variable (Va) regions and several types of beta
chain
variable (Vr3) regions distinguished by their framework, CDR1 and CDR2
sequences,
CA 03056493 2019-09-13
WO 2018/172533 - 6 - PCT/EP2018/057482
and by a partly defined CDR3 sequence. The Va types are referred to in IMGT
nomenclature by a unique TRAV number, V8 types are referred to by a unique
TRBV
number. For more information on immunoglobulin antibody and TCR genes see the
international ImMunoGeneTics information system , Lefranc M-P et al (Nucleic
Acids
Res. 2015 Jan;43(Database issue):D413-22; and http://www.imgtorg/).
Therefore, in one additional or alternative embodiment the antigen recognizing
construct of the invention comprises CDR1, CDR2, CDR2bis and CDR3 sequences in
a combination as provided in Table 1 herein below, which display the
respective
variable chain allele together with the CDR3 sequence. Therefore, preferred
are
antigen recognizing constructs of the invention which comprise at least one,
preferably,
all four CDR sequences CDR1, CDR2, CDR2bis and CDR3. Preferably, an antigen
recognizing construct of the invention comprises the respective CDR1, CDR2bis
and
CDR3 of one individual herein disclosed TCR variable region of the invention
(see
Table 1 herein below and the example section).
The term "specificity" or "antigen specificity" or "specific for" a given
antigen, as used
herein means that the antigen recognizing construct can specifically bind to
said
antigen, preferably a TAA antigen, more preferably with high avidity, when
said antigen
is presented by HLA, preferably by HLA A2. For example, a TCR, as antigen
recognizing construct, may be considered to have "antigenic specificity" for
the TAA, if
T cells expressing the TCR and contacted with a TAA presenting HLA secrete at
least
about 200 pg/ml or more (e.g., 250 pg/ml or more, 300 pg/ml or more, 400 pg/ml
or
more, 500 pg/ml or more, 600 pg/ml or more, 700 pg/ml or more, 1000 pg ml or
more,
2,000 pg/ml or more, 2,500 pg/ml or more, 5,000 pg/ml or more) of interferon y
(IFN-y)
upon co-culture with target cells pulsed with a low concentration of a TAA
antigen,
such as the TAA epitopes and antigens provided herein below (e.g., about 10-11
mo1/1,
10-10 mo1/1, 10-9 mo1/1, 10-8 mo1/1, 10-7 mo1/1, 10-6 mo1/1, 10-5 mo1/1).
Alternatively, or
additionally, a TCR may be considered to have "antigenic specificity" for the
TAA, if T
cells expressing the TCR secrete at least twice as much I FN-y as the non-
transduced
background level of IFN-y upon co-culture with target cells pulsed with a low
concentration of the TAA antigens. Such a "specificity" as described above can
¨ for
example ¨ be analyzed with an ELISA.
CA 03056493 2019-09-13
WO 2018/172533 - 7 - PCT/EP2018/057482
In one alternative or additional embodiment of the invention, the antigen
recognizing
construct selectively binds to a TAA derived antigenic peptide; preferably
wherein the
TAA antigenic peptide is a protein epitope or peptide having an amino acid
sequence
shown in SEQ ID NO: 97 to 115, most preferably SEQ ID NO:97, or a variant
thereof,
wherein the variant is an amino acid deletion, addition, insertion or
substitution of not
more than three, preferably two and most preferably not more than one amino
acid
position.
The term "selectivity" or "selective recognizing/binding" is understood to
refer to the
property of an antigen recognizing construct, such as a TCR or antibody, to
selectively
recognize or bind to preferably only one specific epitope and preferably shows
no or
substantially no cross-reactivity to another epitope. Preferably "selectivity"
or "selective
recognizing/binding" means that the antigen recognizing construct (e.g. a TCR)
selectively recognizes or binds to preferably only one specific epitope and
preferably
shows no or substantially no cross-reactivity to another epitope, wherein said
epitope
is unique for one protein, such that the antigen recognizing construct shows
no or
substantially no cross-reactivity to another epitope and another protein.
The antigen recognizing construct according to the invention is preferably
selected
from an antibody, or derivative or fragment thereof, or a T cell receptor
(TCR), or
derivative or fragment thereof. A derivative or fragment of an antibody or TCR
of the
invention shall preferably retain the antigen binding/recognizing ability of
the parent
molecule, in particular its specificity and/or selectivity as explained above.
Such
binding functionality may be retained by the presence of a CDR3 region as
defined
herein.
In an embodiment of the invention, the inventive TCRs are able to recognize
TAA
antigens in a major histocompatibility complex (MHC) class I-dependent manner.
"MHC
class I-dependent manner," as used herein, means that the TCR elicits an
immune
response upon binding to TAA antigens within the context of an MHC class I
molecule.
The MHC class I molecule can be any MHC class I molecule known in the art,
e.g.,
HLA-A molecules. In a preferred embodiment of the invention, the MHC class I
molecule is an HLA-A2 molecule.
CA 03056493 2019-09-13
WO 2018/172533 - 8 - PCT/EP2018/057482
The invention provides both single chain antigen recognizing construct and
double
chain recognizing constructs.
In an embodiment, the TCR alpha variable domain has at least one mutation
relative to
a TCR alpha domain shown in Table 1; and/or the TCR beta variable domain has
at
least one mutation relative to a TCR alpha domain shown in Table 1. In an
embodiment, a TCR comprising at least one mutation in the TCR alpha variable
domain and/or TCR beta variable domain has a binding affinity for, and/or a
binding
half-life for, a TAA peptide-HLA molecule complex, which is at least double
that of a
TCR comprising the unmutated TCR alpha domain and/or unmutated TCR beta
variable domain.
The TCR alpha chains of the present description may further comprise a TCR
alpha
transmembrane domain and/or a TCR alpha intracellular domain. The TCR beta
chains
of the present description may further comprise a TCR beta transmembrane
domain
and/or a TCR beta intracellular domain.
The invention in particular provides a TCR as antigen recognizing construct,
or
fragment or derivative thereof. The TCR preferably is of human, which is
understood as
being generated from a human TCR locus and therefore comprising human TCR
sequences. Furthermore, the TCR of the invention may be characterized in that
it is of
human origin and specifically recognizes a TAA antigen of the invention.
Another embodiment of the invention additionally or alternatively provides the
antigen
recognizing construct described above, which induces an immune response,
preferably
wherein the immune response is characterized by an increase in interferon
(IFN) y
levels.
TCRs of the invention may be provided as single chain a or [3 , or y and 6,
molecules, or
alternatively as double chain constructs composed of both the a and [3 chain,
or y and
6 chain.
The antigen recognizing construct of the invention may comprise a TCR a or y
chain;
and/or a TCR [3 or 6 chain; wherein the TCR a or y chain comprises a CDR3
having at
CA 03056493 2019-09-13
WO 2018/172533 - 9 - PCT/EP2018/057482
least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an
amino acid sequence selected from SEQ ID Nos. 3, 15, 27, 39, 51, 63, 75, and
129
and/or wherein the TCR [3 or 6 chain comprises a CDR3 having at least 50%,
60%,
70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an amino acid
sequence selected from SEQ ID Nos. 9, 21, 33, 45, 57, 69, 81, and 135.
Most preferably, in some additional embodiments, wherein the disclosure refers
to
antigen recognizing constructs comprising any one, two, three or all of the
CDR1,
CDR2, CDR2bis and CDR3 regions of the herein disclosed TCR chains (see Table
1),
such antigen recognizing constructs may be preferred, which comprise the
respective
CDR sequence of the invention with not more than three, two, and preferably
only one,
modified amino acid residues. A modified amino acid residue may be selected
from an
amino acid insertion, deletion or substitution. Most preferred is that the
three, two,
preferably only one modified amino acid residue is the first or last amino
acid residue of
the respective CDR sequence. If the modification is a substitution, then it is
preferable
in some embodiments that the substitution is a conservative amino acid
substitution.
If the antigen recognizing construct of the invention is composed of at least
two amino
acid chains, such as a double chain TCR, or antigen binding fragment thereof,
the
antigen recognizing construct may comprises in a first polypeptide chain the
amino
acid sequence according to SEQ ID NO: 3, and in a second polypeptide chain the
amino acid sequence according to SEQ ID NO: 9; or in a first polypeptide chain
the
amino acid sequence according to SEQ ID NO: 15, and in a second polypeptide
chain
the amino acid sequence according to SEQ ID NO: 21; or in a first polypeptide
chain
the amino acid sequence according to SEQ ID NO: 27, and in a second
polypeptide
chain the amino acid sequence according to SEQ ID NO: 33; or in a first
polypeptide
chain the amino acid sequence according to SEQ ID NO: 39, and in a second
polypeptide chain the amino acid sequence according to SEQ ID NO: 45; or in a
first
polypeptide chain the amino acid sequence according to SEQ ID NO: 51, and in a
second polypeptide chain the amino acid sequence according to SEQ ID NO: 57;
or in
a first polypeptide chain the amino acid sequence according to SEQ ID NO: 63,
and in
a second polypeptide chain the amino acid sequence according to SEQ ID NO: 69;
or
in a first polypeptide chain the amino acid sequence according to SEQ ID NO:
75, and
in a second polypeptide chain the amino acid sequence according to SEQ ID NO:
81;
CA 03056493 2019-09-13
WO 2018/172533 - 10 - PCT/EP2018/057482
or in a first polypeptide chain the amino acid sequence according to SEQ ID
NO: 129,
and in a second polypeptide chain the amino acid sequence according to SEQ ID
NO:
135. Any one of the aforementioned double chain TCR, or antigen binding
fragments
thereof, are preferred TCR of the present invention. In some embodiments, the
CDR3
of the double chain TCR of the invention may be mutated. Mutations of the CDR3
sequences as provided above preferably include a substitution, deletion,
addition, or
insertion of not more than three, preferably two, and most preferably not more
than one
amino acid residue. In some embodiments, the first polypeptide chain may be a
TCR a
or y chain, and the second polypeptide chain may be a TCR [3 or 6 chain.
Preferred is
the combination of an ar3 or yb TCR.
The TCR, or the antigen binding fragment thereof, is in some embodiments
composed
of a TCR a and a TCR [3 chain, or y and 6 chain. Such a double chain TCR
comprises
within each chain variable regions, and the variable regions each comprise one
CDR1,
one CDR2, or more preferably one CDR2bis, and one CDR3 sequence. The TCRs
comprises the CDR1, CDR2, CDR2bis and CDR3 sequences as comprised in the
variable chain amino acid sequence of SEQ ID NOs: 4 and 10; or 16 and 22; or
28 and
34; 0r40 and 46; 0r52 and 58; 0r64 and 70; 0r76 and 82; or 130 and 136.
Some embodiments of the invention pertain to a TCR, or a fragment thereof,
composed
of a TCR a and a TCR [3 chain, wherein said TCR comprises the variable region
sequences having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
preferably
100% sequence identity to the amino acid sequence selected from the a and 13.
chain
according to SEQ ID NOs: 4 and 10; or 16 and 22; or 28 and 34; or 40 and 46;
or 52
and 58; or 64 and 70; or 76 and 82; or 130 and 136.
In a particularly preferred embodiment, the present invention provides an
improved
TCR, designated as R11P3D3_KE, composed of a TCR a and a TCR [3 chain, wherein
said TCR comprises the variable region sequences having at least 50%, 60%,
70%,
80%, 90%, 95%, 98%, 99%, or preferably 100% sequence identity to the amino
acid
sequence selected from the a and [3 chain according to SEQ ID NOs: 132 and
138. This
TCR showed a surprisingly improved functionality in terms of tumor cell
recognition
when compared to its parent receptor, designated herein as R11P3D3.
CA 03056493 2019-09-13
WO 2018/172533 - 11 - PCT/EP2018/057482
The inventive TCRs may further comprise a constant region derived from any
suitable
species, such as any mammal, e.g., human, rat, monkey, rabbit, donkey, or
mouse. In
an embodiment of the invention, the inventive TCRs further comprise a human
constant region. In some preferred embodiments, the constant region of the TCR
of the
invention may be slightly modified, for example, by the introduction of
heterologous
sequences, preferably mouse sequences, which may increase TCR expression and
stability. In some preferred embodiments, the variable region of the TCR of
the
intervention may be slightly modified, for example, by the introduction of
single point
mutations to optimize the TCR stability and/or to enhance TCR chain pairing.
Some embodiments of the invention pertain to a TCR, or a fragment thereof,
composed
of a TCR a and a TCR [3 chain, wherein said TCR comprises the constant region
having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or preferably 100%
sequence identity to an amino acid sequence selected from of the a and [3
chain
according to SEQ ID NOs: 5 and 11; or 17 and 23; or 29 and 35; or 41 and 47;
or 53
and 59; or 65 and 71; or 77 and 83; or 131 and 137.
The TCR a or y chain of the invention may further comprise a CDR1 having at
least
50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an amino
acid sequence selected from SEQ ID Nos. 1, 13, 25, 37, 49, 61, 73, and 127;
and/or a
CDR2 having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence
identity to an amino acid sequence selected from SEQ ID Nos. 2, 14, 26, 38,
50, 62,
74, and 128; and/or more preferably a CDR2bis having at least 50%, 60%, 70%,
80%,
90%, 95%, 98%, 99%, or 100% sequence identity to an amino acid sequence
selected
from SEQ ID Nos. 196, 197, 198, 199, 200, 201, 202, and 204.
According to the invention the TCR [3 or 6 chain may further comprise a CDR1
having
at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to
an
amino acid sequence selected from SEQ ID Nos. 7, 19, 31, 43, 55, 67, 79, and
133;
and/or a CDR2 having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100%
sequence identity to an amino acid sequence selected from SEQ ID Nos. 8, 20,
32, 44,
56, 68, 80, and 134; and/or more preferably a CDR2bis having at least 50%,
60%,
70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an amino acid
sequence selected from SEQ ID Nos. 8, 20, 32, 44, 56, 68, 80, and 134.
CA 03056493 2019-09-13
WO 2018/172533 - 12 - PCT/EP2018/057482
The antigen recognizing construct may in a further embodiment comprise a
binding
fragment of a TCR, and wherein said binding fragment comprises in one chain
CDR1,
CDR2, CDR2bis and CDR3, optionally selected from the CDR1, CDR2, CDR2bis and
CDR3 sequences having the amino acid sequences of SEQ ID Nos. 1, 2, 3, 196; or
7,
8, 9; or 13, 14, 15, 197; or 19, 20, 21; or 25, 26, 27, 198; or 31, 32, 33; or
37, 38, 39,
199; 0r43, 44, 45; 0r49, 50, 51, 200; or 55, 56, 57; or 61, 62, 63, 201; or
67, 68, 69; or
73, 74, 75, 202; or 79, 80, 81; or 127, 128, 129, 204; or 133, 134,135.
In further embodiments of the invention the antigen recognizing construct as
described
herein elsewhere is a TCR, or a fragment thereof, composed of at least one TCR
a and
one TCR [3 chain sequence, wherein said TCR a chain sequence comprises the
CDR1,
CDR2, CDR2bis and CDR3 sequences having the amino acid sequences of SEQ ID
NO: 1 to 3 and 196, and said TCR [3 chain sequence comprises the CDR1 to CDR3
sequences having the amino acid sequences of SEQ ID NO: 7 to 9; or wherein
said
TCR a chain sequence comprises the CDR1, CDR2, CDR2bis and CDR3 sequences
having the amino acid sequences of SEQ ID NO: 13 to 15 and 197, and said TCR
13.
chain sequence comprises the CDR1 to CDR3 sequences having the amino acid
sequences of SEQ ID NO: 19 to 21; or wherein said TCR a chain sequence
comprises
the CDR1, CDR2, CDR2bis and CDR3 sequences having the amino acid sequences of
SEQ ID NO: 25 to 27 and 198, and said TCR [3 chain sequence comprises the CDR1
to
CDR3 sequences having the amino acid sequences of SEQ ID NO: 31 to 33; or
wherein said TCR a chain sequence comprises the CDR1, CDR2, CDR2bis and CDR3
sequences having the amino acid sequences of SEQ ID NO: 37 to 39 and 199, and
said TCR [3 chain sequence comprises the CDR1 to CDR3 sequences having the
amino acid sequences of SEQ ID NO: 43 to 45; or wherein said TCR a chain
sequence
comprises the CDR1, CDR2, CDR2bis and CDR3 sequences having the amino acid
sequences of SEQ ID NO: 49 to 51 and 200, and said TCR [3 chain sequence
comprises the CDR1 to CDR3 sequences having the amino acid sequences of SEQ ID
NO: 55 to 57; or wherein said TCR a chain sequence comprises the CDR1, CDR2,
CDR2bis and CDR3 sequences having the amino acid sequences of SEQ ID NO: 61 to
63 and 201, and said TCR i3 chain sequence comprises the CDR1 to CDR3
sequences
having the amino acid sequences of SEQ ID NO: 67 to 69; or wherein said TCR a
chain sequence comprises the CDR1, CDR2, CDR2bis and CDR3 sequences having
CA 03056493 2019-09-13
WO 2018/172533 - 13 - PCT/EP2018/057482
the amino acid sequences of SEQ ID NO: 73 to 75 and 202, and said TCR [3 chain
sequence comprises the CDR1 to CDR3 sequences having the amino acid sequences
of SEQ ID NO: 79 to 81; or wherein said TCR a chain sequence comprises the
CDR1,
CDR2, CDR2bis and CDR3 sequences having the amino acid sequences of SEQ ID
NO: 127 to 129 and 204, and said TCR [3 chain sequence comprises the CDR1 to
CDR3 sequences having the amino acid sequences of SEQ ID NO: 133 to 135.
In further embodiments of the invention the antigen recognizing construct as
described
herein before is a TCR, or a fragment thereof, comprising at least one TCR a
and one
TCR [3 chain sequence, wherein said TCR a chain sequence comprises a variable
region sequence having the amino acid sequence of SEQ ID No. 4, and wherein
said
TCR [3 chain sequence comprises a variable region sequence having the amino
acid
sequence of SEQ ID No. 10; or wherein said TCR a chain sequence comprises a
variable region sequence having the amino acid sequence of SEQ ID No. 16, and
wherein said TCR [3 chain sequence comprises a variable region sequence having
the
amino acid sequence of SEQ ID No. 22; or wherein said TCR a chain sequence
comprises a variable region sequence having the amino acid sequence of SEQ ID
No.
28, and wherein said TCR [3 chain sequence comprises a variable region
sequence
having the amino acid sequence of SEQ ID No. 34; or wherein said TCR a chain
sequence comprises a variable region sequence having the amino acid sequence
of
SEQ ID No. 40, and wherein said TCR i3 chain sequence comprises a variable
region
sequence having the amino acid sequence of SEQ ID No. 46; or wherein said TCR
a
chain sequence comprises a variable region sequence having the amino acid
sequence of SEQ ID No. 52, and wherein said TCR [3 chain sequence comprises a
variable region sequence having the amino acid sequence of SEQ ID No. 58; or
wherein said TCR a chain sequence comprises a variable region sequence having
the
amino acid sequence of SEQ ID No. 64, and wherein said TCR [3 chain sequence
comprises a variable region sequence having the amino acid sequence of SEQ ID
No.
70; or wherein said TCR a chain sequence comprises a variable region sequence
having the amino acid sequence of SEQ ID No. 76, and wherein said TCR 13.
chain
sequence comprises a variable region sequence having the amino acid sequence
of
SEQ ID No. 82; or wherein said TCR a chain sequence comprises a variable
region
sequence having the amino acid sequence of SEQ ID No. 130, and wherein said
TCR
[3 chain sequence comprises a variable region sequence having the amino acid
CA 03056493 2019-09-13
WO 2018/172533 - 14 - PCT/EP2018/057482
sequence of SEQ ID No. 136.
In further embodiments of the invention the antigen recognizing construct as
described
herein before is a TCR, or a fragment thereof, further comprising a TCR
constant
region having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100%
sequence
identity to an amino acid sequence selected from SEQ ID Nos. 5, 11, 17, 23,
29, 35,
41, 47, 53, 59, 65, 71, 77, 83, 131, and 137 preferably wherein the TCR is
composed
of at least one TCR a and one TCR [3 chain sequence, wherein the TCR a chain
sequence comprises a constant region having at least 50%, 60%, 70%, 80%, 90%,
95%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected
from
SEQ ID Nos. 5, 17, 29, 41, 53, 65, 77, and 131; and wherein the TCR [3 chain
sequence comprises a constant region having at least 50%, 60%, 70%, 80%, 90%,
95%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected
from
SEQ ID Nos. 11, 23, 35, 47, 59, 71, 83, and 137.
Also disclosed are antigen recognizing constructs as described herein before
comprising a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 6, and
a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 12. The
invention
also provides TCRs comprising a first TCR chain having at least 50%, 60%, 70%,
80%,
90%, 95%, 98%, 99%, or 100% sequence identity to the amino acid sequence of
SEQ
ID No. 18, and a second TCR chain having at least 50%, 60%, 70%, 80%, 90%,
95%,
98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID No.
24.
In further embodiments, the invention provides antigen recognizing constructs
which
are TCR and comprise a first TCR chain having at least 50%, 60%, 70%, 80%,
90%,
95%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID
No.
30, and a second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 36. In
further embodiments, the invention provides antigen recognizing constructs
which are
TCR and comprise a first TCR chain having at least 50%, 60%, 70%, 80%, 90%,
95%,
98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID No.
42,
and a second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%,
or 100% sequence identity to the amino acid sequence of SEQ ID No. 48. In
further
CA 03056493 2019-09-13
WO 2018/172533 - 15 - PCT/EP2018/057482
embodiments, the invention provides antigen recognizing constructs which are
TCR
and comprise a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 54,
and a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 60. In further
embodiments, the invention provides antigen recognizing constructs which are
TCR
and comprise a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No.66, and
a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 72. In further
embodiments, the invention provides antigen recognizing constructs which are
TCR
and comprise a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 78,
and a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 84. In further
embodiments, the invention provides antigen recognizing constructs which are
TCR
and comprise a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 132,
and a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 138.
As used herein, the term "murine" or "human," when referring to an antigen
recognizing
construct, or a TCR, or any component of a TCR described herein (e.g.,
complementarity determining region (CDR), variable region, constant region, a
chain,
and/or [3 chain), means a TCR (or component thereof), which is derived from a
mouse
or a human unrearranged TCR locus, respectively.
In an embodiment of the invention, chimeric TCR are provided, wherein the TCR
chains comprise sequences from multiple species. Preferably, a TCR of the
invention
may comprise an a chain comprising a human variable region of an a chain and,
for
example, a murine constant region of a murine TCR a chain.
In one embodiment, the TCR of the invention is a human TCR comprising human
variable regions according to the above embodiments and human constant
regions.
CA 03056493 2019-09-13
WO 2018/172533 - 16 - PCT/EP2018/057482
In some embodiments, the antigen recognizing construct is murinized or
humanized.
These terms are used when amino acid sequences from a foreign species are
introduced into a construct of the invention.
The TCR of the invention may be provided as a single chain TCR (scTCR). A
scTCR
according to the invention shall comprise in one polypeptide chain a full or
partial alpha
chain sequence and a full or partial beta chain sequence, preferably connected
via a
peptide linker. A scTCR can comprise a polypeptide of a variable region of a
first TCR
chain (e.g., an alpha chain) and a polypeptide of an entire (full-length)
second TCR
chain (e.g., a beta chain), or vice versa. Furthermore, the scTCR can
optionally
comprise one or more linkers which join the two or more polypeptides together.
The
linker can be, for instance, a peptide, which joins together two single
chains, as
described herein. Also provided is such a scTCR of the invention, which is
fused to a
human cytokine, such as IL-2, IL-7 or IL-15.
The antigen recognizing construct according to the invention can also be
provided in
the form of a multimeric complex, comprising at least two scTCR molecules,
wherein
said scTCR molecules are each fused to at least one biotin moiety, or other
interconnecting molecule/linker, and wherein said scTCRs are interconnected by
biotin-streptavidin interaction to allow the formation of said multimeric
complex. Similar
approaches known in the art for the generation of multimeric TCR are also
possible
and included in this disclosure. Also provided are multimeric complexes of a
higher
order, comprising more than two scTCR of the invention.
For the purposes of the present invention, a TCR is a moiety having at least
one TCR
alpha or gamma and/or TCR beta or delta variable domain. Generally, they
comprise
both a TCR alpha variable domain and a TCR beta variable domain, alternatively
both
a TCR gamma variable domain and a TCR delta variable domain. They may be
ar3/y6
heterodimers or may be in single chain format. For use in adoptive therapy, an
a13 or yb
heterodimeric TCR may, for example, be transfected as full-length chains
having both
cytoplasmic and transmembrane domains. If desired, an introduced disulfide
bond
between residues of the respective constant domains may be present.
CA 03056493 2019-09-13
WO 2018/172533 - 17 - PCT/EP2018/057482
In a preferred embodiment, the antigen recognizing construct is a human TCR,
or
fragment or derivative thereof. A human TCR or fragment or derivative thereof
is a
TCR, which comprises over 50% of the corresponding human TCR sequence.
Preferably, only a small part of the TCR sequence is of artificial origin or
derived from
other species. It is known, however, that chimeric TCRs, e.g. derived from
human
origin with murine sequences in the constant domains, are advantageous.
Particularly
preferred are, therefore, TCRs in accordance with the present invention, which
contains murine sequences in the extracellular part of their constant domains.
Thus, it is also preferred that the inventive antigen recognizing construct is
able to
recognize its antigen in a human leucocyte antigen (HLA) dependent manner,
preferably in a HLA-A*02 dependent manner. The term "HLA dependent manner" in
the context of the present invention means that the antigen recognizing
construct binds
to the antigen only in the event that the antigenic peptide is presented by
said HLA.
The antigen recognizing construct in accordance with the invention in one
embodiment
preferably induces an immune response, preferably wherein the immune response
is
characterized by the increase in interferon (IFN) y levels.
Also, provided by the invention is a polypeptide comprising a functional
portion of any
of the TCRs (or functional variants thereof) described herein, for examples,
of any one
of the TCRs selected from R11P3D3, R16P1C10, R16P1E8, R17P1A9, R17P1D7,
R17P1G3, R17P2B6 and R11P3D3_KE, as provided in the example section and Table
1. The term "polypeptide" as used herein includes oligopeptides and refers to
a single
chain of amino acids connected by one or more peptide bonds. With respect to
the
inventive polypeptides, the functional portion can be any portion comprising
contiguous
amino acids of the TCR (or functional variant thereof), of which it is a part,
provided
that the functional portion specifically binds to the TAA antigen, preferably
as disclosed
herein in Table 2, and peptides Al to A9 (SEQ ID NOs:97, and 98-106, and the
peptides Ti to T9 (SEQ ID NOs:107-115)). The term "functional portion" when
used in
reference to a TCR (or functional variant thereof) refers to any part or
fragment of the
TCR (or functional variant thereof) of the invention, which part or fragment
retains the
biological activity of the TCR (or functional variant thereof), of which it is
a part (the
parent TCR or parent functional variant thereof). Functional portions
encompass, for
CA 03056493 2019-09-13
WO 2018/172533 - 18 - PCT/EP2018/057482
example, those parts of a TCR (or functional variant thereof) that retain the
ability to
specifically bind to the TAA antigen (in an HLA dependent manner), or detect,
treat, or
prevent cancer, to a similar extent, the same extent, or to a higher extent,
as the parent
TCR (or functional variant thereof). In reference to the parent TCR (or
functional
variant thereof), the functional portion can comprise, for instance, about
10%, 25%,
30%, 50%, 68%, 80%, 90%, 95%, or more, of the parent TCR variable sequences
(or
functional variant thereof).
The functional portion can comprise additional amino acids at the amino or
carboxy
terminus of the portion, or at both termini, in which additional amino acids
are not found
in the amino acid sequence of the parent TCR or functional variant thereof.
Desirably,
the additional amino acids do not interfere with the biological function of
the functional
portion, e.g., specifically binding to the TAA antigens; and/or having the
ability to detect
cancer, treat or prevent cancer, etc. More desirably, the additional amino
acids
enhance the biological activity, as compared to the biological activity of the
parent TCR
or functional variant thereof.
The polypeptide can comprise a functional portion of either or both of the a
and 13
chains of the TCRs or functional variant thereof of the invention, such as a
functional
portion comprising one of more of CDR1, CDR2, CDR2bis and (preferably) CDR3 of
the variable region(s) of the a chain and/or 13 chain of a TCR or functional
variant
thereof of the invention. In an embodiment of the invention, the polypeptide
can
comprise a functional portion comprising the amino acid sequence of SEQ ID NO:
3, 9,
15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 129, and 135 (CDR3 of the
variable
regions of the TCR of the invention), or a combination thereof. In an
embodiment of the
invention, the inventive polypeptide can comprise, for instance, the variable
region of
the inventive TCR or functional variant thereof comprising a combination of
the CDR
regions set forth above. In this regard, the polypeptide can comprise the
amino acid
sequence of any of SEQ ID NO: 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70,
76, 82,
130, and 136 (the variable regions of an a or 13 chain of the TCR of the
invention).
In some instances, the construct of the invention may comprise one or two
polypeptide
chains comprising a sequence according to any of the SEQ ID NO: 1 to 84 and
127 to
138 and 196 to 202 and 204 (CDR sequences, constant and variable regions and
full
CA 03056493 2019-09-13
WO 2018/172533 - 19 - PCT/EP2018/057482
length sequences), or functional fragments thereof, and further comprise(s)
other
amino acid sequences, e.g., an amino acid sequence encoding an immunoglobulin
or
a portion thereof, then the inventive protein can be a fusion protein. In this
regard, the
invention also provides a fusion protein comprising at least one of the
inventive
polypeptides described herein along with at least one other polypeptide. The
other
polypeptide can exist as a separate polypeptide of the fusion protein, or can
exist as a
polypeptide, which is expressed in frame (in tandem) with one of the inventive
polypeptides described herein. The other polypeptide may include any peptidic
or
proteinaceous molecule, or a portion thereof, including, but not limited to an
immunoglobulin, CD3, CD4, CD8, an MHC molecule, a CD1 molecule, e.g., CD1a,
CD1b, CD1c, CD1d, etc.
The fusion protein can comprise one or more copies of the inventive
polypeptide and/or
one or more copies of the other polypeptide. For instance, the fusion protein
can
comprise 1, 2, 3, 4, 5, or more, copies of the inventive polypeptide and/or of
the other
polypeptide. Suitable methods of making fusion proteins are known in the art,
and
include, for example, recombinant methods. In some embodiments of the
invention, the
TCRs (and functional portions and functional variants thereof), polypeptides,
and
proteins of the invention may be expressed as a single protein comprising a
linker
peptide linking the a chain and the 13 chain, and linking the y chain and the
6 chain. In
this regard, the TCRs (and functional variants and functional portions
thereof),
polypeptides, and proteins of the invention comprising the amino acid
sequences of the
variable regions of the TCR of the invention and may further comprise a linker
peptide.
The linker peptide may advantageously facilitate the expression of a
recombinant TCR
(including functional portions and functional variants thereof), polypeptide,
and/or
protein in a host cell. The linker peptide may comprise any suitable amino
acid
sequence. Linker sequences for single chain TCR constructs are well known in
the art.
Such a single chain construct may further comprise one, or two, constant
domain
sequences. Upon expression of the construct including the linker peptide by a
host cell,
the linker peptide may also be cleaved, resulting in separated a and 13
chains, and
separated y and 6 chain.
As already mentioned above, the binding functionality of the TCR of the
invention may
be provided in the framework of an antibody. For example, CDR sequences of the
TCR
CA 03056493 2019-09-13
WO 2018/172533 - 20 - PCT/EP2018/057482
of the invention, possibly including additional 3, 2 or 1 N and/or C terminal
framework
residues, may be directly grafted into an antibody variable heavy/light chain
sequence.
The term "antibody" in its various grammatical forms is used herein to refer
to
immunoglobulin molecules and immunologically active portions of immunoglobulin
molecules, i.e., molecules that contain an antigen-binding site or a paratope.
Such
molecules are also referred to as "antigen binding fragments" of
immunoglobulin
molecules. The invention further provides an antibody, or antigen binding
portion
thereof, which specifically binds to the antigens described herein. The
antibody can be
any type of immunoglobulin that is known in the art. For instance, the
antibody can be
of any isotype, e.g., IgA, IgD, IgE, IgG, IgM, etc. The antibody can be
monoclonal or
polyclonal. The antibody can be a naturally-occurring antibody, e.g., an
antibody
isolated and/or purified from a mammal, e.g., mouse, rabbit, goat, horse,
chicken,
hamster, human, etc. Alternatively, the antibody can be a genetically-
engineered
antibody, e.g., a humanized antibody or a chimeric antibody. The antibody can
be in
monomeric or polymeric form.
The term "antibody" includes, but is not limited to, genetically engineered or
otherwise
modified forms of immunoglobulins, such as intrabodies, chimeric antibodies,
fully
human antibodies, humanized antibodies (e.g. generated by "CDR-grafting"),
antibody
fragments, and heteroconjugate antibodies (e.g., bispecific antibodies,
diabodies,
triabodies, tetra-bodies, etc.). The term "antibody" includes cys-diabodies
and
minibodies. Thus, each and every embodiment provided herein in regard to
"antibodies", or "antibody like constructs" is also envisioned as, bi-specific
antibodies,
diabodies, scFv fragments, chimeric antibody receptor (CAR) constructs,
diabody
and/or minibody embodiments, unless explicitly denoted otherwise. The term
"antibody" includes a polypeptide of the immunoglobulin family or a
polypeptide
comprising fragments of an immunoglobulin that is capable of non-covalently,
reversibly, and in a specific manner binding a corresponding antigen,
preferably the
TAA of the invention, as disclosed herein. An exemplary antibody structural
unit
comprises a tetramer. In some embodiments, a full-length antibody can be
composed
of two identical pairs of polypeptide chains, each pair having one "light" and
one
"heavy" chain (connected through a disulfide bond). Antibody structure and
isotypes
are well known to the skilled artisan (for example from Janeway's
lmmunobiology, 9th
edition, 2016).
CA 03056493 2019-09-13
WO 2018/172533 - 21 - PCT/EP2018/057482
The recognized immunoglobulin genes of mammals include the kappa, lambda,
alpha,
gamma, delta, epsilon, and mu constant region genes, as well as the myriad
immunoglobulin variable region genes (for more information on immunoglobulin
genes
see the international Im-MunoGeneTics information system , Lefranc M-P et al,
Nucleic Acids Res. 2015 Jan;43(Database
issue):D413-22; and
http://www.imgt.org/). For full-length chains, the light chains are
classified as either
kappa or lambda. For full-length chains, the heavy chains are classified as
gamma,
mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes,
IgG, IgM,
IgA, IgD, and IgE, respectively. The N-terminus of each chain defines a
variable region
of about 100 to 110 or more amino acids primarily responsible for antigen
recognition.
The terms variable light chain (VL) and variable heavy chain (VH) refer to
these
regions of light and heavy chains respectively. As used in this invention, an
"antibody"
encompasses all variations of antibody and fragments thereof. Thus, within the
scope
of this concept are full length antibodies, chimeric antibodies, humanized
antibodies,
single chain antibodies (scFv), Fab, Fab', and multimeric versions of these
fragments
(e.g., F(ab')2) with the same, essentially the same or similar binding
specificity. In
some embodiments, the anti-body binds specifically to a peptide TAA of the
invention.
Preferred antigen recognizing constructs according to the invention include an
antibody
heavy chain, preferably the variable domain thereof, or an antigen binding
fragment
thereof, and/or an antibody light chain, preferably the variable domain
thereof, or an
antigen binding fragment thereof. Similarly, disulfide-stabilized variable
region
fragments (dsFv) can be prepared by recombinant DNA technology, antibody
fragments of the invention, however, are not limited to these exemplary types
of
antibody fragments. Also, the antibody, or antigen binding portion thereof,
can be
modified to comprise a detectable label, such as, for instance, a
radioisotope, a
fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE)), an
enzyme
(e.g., alkaline phosphatase, horseradish peroxidase), and element particles
(e.g., gold
particles). In some instances, the TCR CDR3 sequence may be slightly modified,
but
preferably by not more than 3 amino acid residues, preferably only two and
most
preferably only one amino acid position, as compared to the CDR3 sequences
provided in SEQ ID Nos: 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81,
129, and
135. Preferably, the antibodies comprise the CDR3, preferably all of CDR1,
CDR2,
CDR2bis and CDR3 regions in the combination, as indicated for the TCR of the
CA 03056493 2019-09-13
WO 2018/172533 - 22 - PCT/EP2018/057482
invention in Table 1, in each case independently, optionally with not more
than three or
two, preferably one, amino acid substitution(s), insertion(s) and/or
deletion(s)
compared to these sequences.
Suitable methods of making antibodies are known in the art. For instance,
standard
hybridoma methods are described in, e.g., Kohler and Milstein, Eur. J.
lmmunol, 5, 51
1-519 (1976), Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH
Press
(1988), and C.A. Janeway et al. (eds.), lmmunobiology, 8 Ed., Garland
Publishing,
New York, NY (201 1)). Alternatively, other methods, such as EBV-hybridoma
methods
(Haskard and Archer, J. lmmunol. Methods, 74(2), 361-67 (1984), and Roder et
al,
Methods Enzymol, 121, 140-67 (1986)), and bacteriophage vector expression
systems
(see, e.g., Huse et al., Science, 246, 1275-81 (1989)) are known in the art.
Further,
methods of producing antibodies in non-human animals are described in, e.g.,
U.S.
Patents 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application
Publication
No. 2002/0197266.
Some embodiments of the invention also pertain to TCRs, or functional
fragments and
polypeptides thereof, which are soluble TCRs. As used herein, the term
"soluble T-cell
receptor" refers to heterodimeric truncated variants of native TCRs, which
comprise
extracellular portions of the TCR a-chain and 13-chain, for example linked by
a disulfide
bond, but which lack the transmembrane and cytosolic domains of the native
protein.
The terms "soluble T-cell receptor a-chain sequence and soluble T-cell
receptor 13-
chain sequence" refer to TCR a-chain and 13-chain sequences that lack the
transmembrane and cytosolic domains. The sequence (amino acid or nucleic acid)
of
the soluble TCR a-chain and 13-chains may be identical to the corresponding
sequences in a native TCR or may comprise variant soluble TCR a-chain and [3-
chain
sequences, as compared to the corresponding native TCR sequences. The term
"soluble T-cell receptor" as used herein encompasses soluble TCRs with variant
or
non-variant soluble TCR a-chain and 13-chain sequences. The variations may be
in the
variable or constant regions of the soluble TCR a-chain and 13-chain sequences
and
can include, but are not limited to, amino acid deletion, insertion,
substitution mutations
as well as changes to the nucleic acid sequence, which do not alter the amino
acid
sequence. Soluble TCR of the invention in any case retain the binding
functionality of
their parent molecules.
CA 03056493 2019-09-13
WO 2018/172533 - 23 - PCT/EP2018/057482
The above problem is further solved by a nucleic acid encoding for an antigen
recognizing construct of the invention, or any of the aforementioned protein
or
polypeptide constructs. The nucleic acid preferably (a) has a strand encoding
for an
antigen recognizing construct according to the invention; (b) has a strand
complementary to the strand in (a); or (c) has a strand that hybridizes under
stringent
conditions with a molecule as described in (a) or (b). Stringent conditions
are known to
the person of skill in the art, specifically from Sambrook et al, "Molecular
Cloning". In
addition to that, the nucleic acid optionally has further sequences, which are
necessary
for expressing the nucleic acid sequence corresponding to the protein,
specifically for
expression in a mammalian/human cell. The nucleic acid used can be contained
in a
vector suitable for allowing expression of the nucleic acid sequence
corresponding to
the peptide in a cell. However, the nucleic acids can also be used to
transform an
antigen-presenting cell, which may not be restricted to classical antigen-
presenting
cells, such as dendritic cells, in such a way that they themselves produce the
corresponding proteins on their cellular surface.
In some embodiments, the polypeptides of the antigen recognizing constructs
can be
encoded by nucleic acids and expressed in vivo or in vitro. Thus, in some
embodiments, a nucleic acid encoding an antigen recognizing construct is
provided. In
some embodiments, the nucleic acid encodes one part or monomer of an antigen
recognizing construct of the invention (for example one of two chains of a TCR
of the
invention), and/or another nucleic acid encodes another part or monomer of an
antigen
recognizing construct of the invention (for example the other of two chains of
the TCR).
In some embodiments, the nucleic acid encodes two or more antigens recognizing
construct polypeptide chains, for example, at least 2 TCR chains. Nucleic
acids
encoding multiple antigen recognizing construct chains can include nucleic
acid
cleavage sites between at least two chain sequences, can encode transcription
or
translation start site between two or more chains sequences, and/or can encode
proteolytic target sites between two or more antigen recognizing construct
chains.
By "nucleic acid" as used herein includes "polynucleotide," "oligonucleotide,"
and
"nucleic acid molecule," and generally means a polymer of DNA or RNA, which
can be
single-stranded or double-stranded, synthesized or obtained (e.g., isolated
and/or
CA 03056493 2019-09-13
WO 2018/172533 - 24 - PCT/EP2018/057482
purified) from natural sources, which can contain natural, non-natural or
altered
nucleotides, and can contain a natural, non-natural or altered internucleotide
linkage,
such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of
the
phosphodiester found between the nucleotides of an unmodified oligonucleotide.
Preferably, the nucleic acids of the invention are recombinant. As used
herein, the term
"recombinant" refers to (i) molecules that are constructed outside living
cells by joining
natural or synthetic nucleic acid segments to nucleic acid molecules that can
replicate
in a living cell, or (ii) molecules that result from the replication of those
described in (i)
above. For purposes, herein, the replication can be in vitro replication or in
vivo
replication. The nucleic acid can comprise any nucleotide sequence, which
encodes
any of the TCRs, polypeptides, or proteins, or functional portions or
functional variants
thereof described herein.
Furthermore, the invention provides a vector comprising a nucleic acid in
accordance
to the invention as described above. Desirably, the vector is an expression
vector or a
recombinant expression vector. The term "recombinant expression vector" refers
in
context of the present invention to a nucleic acid construct that allows for
the
expression of an mRNA, protein or polypeptide in a suitable host cell. The
recombinant
expression vector of the invention can be any suitable recombinant expression
vector,
and can be used to transform or transfect any suitable host. Suitable vectors
include
those designed for propagation and expansion or for expression or both, such
as
plasmids and viruses. Examples of animal expression vectors include pEUK-CI,
pMAM,
and pMAMneo. Preferably, the recombinant expression vector is a viral vector,
e.g., a
retroviral vector. The recombinant expression vector comprises regulatory
sequences,
such as transcription and translation initiation and termination codons, which
are
specific to the type of host cell (e.g., bacterium, fungus, plant, or animal),
into which the
vector is to be introduced and in which the expression of the nucleic acid of
the
invention may be performed. Furthermore, the vector of the invention may
include one
or more marker genes, which allow for selection of transformed or transfected
hosts.
The recombinant expression vector can comprise a native or normative promoter
operably linked to the nucleotide sequence encoding the constructs of the
invention, or
to the nucleotide sequence, which is complementary to or which hybridizes to
the
nucleotide sequence encoding the constructs of the invention. The selections
of
CA 03056493 2019-09-13
WO 2018/172533 - 25 - PCT/EP2018/057482
promoters include, e.g., strong, weak, inducible, tissue-specific and
developmental-
specific promoters. The promoter can be a non-viral promoter or a viral
promoter. The
inventive recombinant expression vectors can be designed for either transient
expression, for stable expression, or for both. Also, the recombinant
expression vectors
can be made for constitutive expression or for inducible expression.
The invention also pertains to a host cell comprising an antigen recognizing
construct
in accordance with the invention. Specifically, the host cell of the invention
comprises a
nucleic acid, or a vector as described herein above. The host cell can be a
eukaryotic
cell, e.g., plant, animal, fungi, or algae, or can be a prokaryotic cell,
e.g., bacteria or
protozoa. The host cell can be a cultured cell or a primary cell, i.e.,
isolated directly
from an organism, e.g., a human. The host cell can be an adherent cell or a
suspended
cell, i.e., a cell that grows in suspension. For purposes of producing a
recombinant
TCR, polypeptide, or protein, the host cell is preferably a mammalian cell.
Most
preferably, the host cell is a human cell. While the host cell can be of any
cell type, can
originate from any type of tissue, and can be of any developmental stage, the
host cell
preferably is a peripheral blood leukocyte (PBL) or a peripheral blood
mononuclear cell
(PBMC). More preferably, the host cell is a T cell. The T cell can be any T
cell, such as
a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell
line, e.g.,
Jurkat, SupT1, etc., or a T cell obtained from a mammal, preferably a T cell
or T cell
precursor from a human patient. If obtained from a mammal, the T cell can be
obtained
from numerous sources, including but not limited to blood, bone marrow, lymph
node,
the thymus, or other tissues or fluids. T cells can also be enriched for or
purified.
Preferably, the T cell is a human T cell. More preferably, the T cell is a T
cell isolated
from a human. The T cell can be any type of T cell and can be of any
developmental
stage, including but not limited to, CD4-positive and/or CD8- positive, CD4-
positive
helper T cells, e.g., Th1 and Th2 cells, CD8-positive T cells (e.g., cytotoxic
T cells),
tumor infiltrating cells (TILs), memory T cells, naive T cells, and the like.
Preferably, the
T cell is a CD8-positive T cell or a CD4-positive T cell.
Preferably, the host cell of the invention is a lymphocyte, preferably, a T
lymphocyte,
such as a CD4-positive or CD8-positive T-cell. The host cell furthermore
preferably is a
tumor reactive T cell specific for TAA expressing tumor cells.
CA 03056493 2019-09-13
WO 2018/172533 - 26 - PCT/EP2018/057482
The objective of the invention is also solved by a method of manufacturing a
TAA
specific antigen recognizing construct, or of a TAA specific antigen
recognizing
construct expressing cell line, comprising
a. Providing a suitable host cell,
b. Providing a genetic construct comprising a coding sequence encoding for an
antigen recognizing construct according to the herein disclosed invention,
c. Introducing into said suitable host cell said genetic construct, and
d. Expressing said genetic construct by said suitable host cell.
The method may further comprise a step of cell surface presentation of said
antigen
recognizing construct on said suitable host cell.
In other preferred embodiments, the genetic construct is an expression
construct
comprising a promoter sequence operably linked to said coding sequence.
Preferably,
said antigen recognizing construct is of mammalian origin, preferably of human
origin.
The preferred suitable host cell for use in the method of the invention is a
mammalian
cell, such as a human cell, in particular a human T lymphocyte. T cells for
use in the
invention are described in detail herein above.
Also, encompassed by the invention are embodiments, wherein said antigen
recognizing construct is a modified TCR, wherein said modification is the
addition of
functional domains, such as a label or a therapeutically active substance.
Furthermore,
encompassed are TCR having alternative domains, such as an alternative
membrane
anchor domain instead of the endogenous transmembrane region. Also,
encompassed are TCR having point mutations in the TCR variable domain or
constant domain in order to improve TCR expression or stability and/or chain
pairing.
Desirably, the transfection system for introducing the genetic construct into
said
suitable host cell is a retroviral vector system. Such systems are well known
to the
skilled artisan.
Also, comprised by the present invention is in one embodiment the additional
method
step of isolation and purification of the antigen recognizing construct from
the cell and,
optionally, the reconstitution of the translated antigen recognizing construct-
fragments
CA 03056493 2019-09-13
WO 2018/172533 - 27 - PCT/EP2018/057482
in a T-cell.
In an alternative aspect of the invention a T-cell is provided obtained or
obtainable by a
method for the production of a T cell receptor (TCR), which is specific for
tumorous
cells and has high avidity as described herein above. Such a T cell is
depending on the
host cell used in the method of the invention, for example, a human or non-
human T-
cell, preferably a human TCR.
The term "isolated" as used herein in the context of a polypeptide, such as an
antigen
recognizing construct (an example of which could be an antibody), refers to a
polypeptide that is purified from proteins or polypeptides or other
contaminants that
would interfere with its therapeutic, diagnostic, prophylactic, research or
other use. An
antigen recognizing construct according to the invention may be a recombinant,
synthetic or modified (non-natural) antigen binding construct. The term
"isolated" as
used herein in the context of a nucleic acid or cells refers to a nucleic acid
or cells that
is/are purified from DNA, RNA, proteins or polypeptides or other contaminants
(such
as other cells) that would interfere with its therapeutic, diagnostic,
prophylactic,
research or other use, or it refers to a recombinant, synthetic or modified
(non-natural)
nucleic acid. In this context, a "recombinant" protein/polypeptide or nucleic
acid is one
made using recombinant techniques. Methods and techniques for the production
of
recombinant nucleic acids and proteins are well known in the art.
One additional aspect of the present invention relates to the herein disclosed
antigen
recognizing constructs, nucleic acids, vectors, pharmaceutical compositions
and/or
host cell for use in medicine. The use in medicine in one preferred embodiment
includes the use in the diagnosis, prevention and/or treatment of a tumor
disease, such
as a malignant or benign tumor disease. The tumor disease is, for example, a
tumor
disease characterized by the expression of the TAA, in a cancer or tumor cell
of said
tumor disease.
With respect to the above mentioned medical applications of the antigen
recognizing
constructs and other materials derived therefrom, pertaining thereto or
encoding the
same, in accordance of the present disclosure, the to be treated and/or to be
diagnosed diseases can be any proliferative disorder, preferably characterized
by the
CA 03056493 2019-09-13
WO 2018/172533 - 28 - PCT/EP2018/057482
expression of the TAA or TAA epitope sequence of the invention, for example
any
cancer, including any of acute lymphocytic cancer, acute myeloid leukemia,
alveolar
rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the
anus,
anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile
duct, cancer
of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose,
nasal
cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer
of the
vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer,
esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, glioma,
Hodgkin
lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung
cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx
cancer,
non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the
penis,
pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer,
prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine
cancer, soft
tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of
the uterus,
ureter cancer, and urinary bladder cancer. A preferred cancer is cancer of the
uterine
cervix, oropharynx, anus, anal canal, anorectum, vagina, vulva, or penis. A
particularly
preferred cancer is a TAA positive cancer, including preferably ovarian
carcinoma,
leukemia or melanoma.
The constructs, proteins, TCRs antibodies, polypeptides and nucleic acids of
the
invention are in particular for use in immune therapy, preferably, in adoptive
T cell
therapy. The administration of the compounds of the invention can, for
example,
involve the infusion of T cells of the invention into said patient.
Preferably, such T cells
are autologous T cells of the patient and in vitro transduced with a nucleic
acid or
antigen recognizing construct of the present invention.
The inventive antigen recognizing constructs, TCRs, polypeptides, proteins
(including
functional variants thereof), nucleic acids, recombinant expression vectors,
host cells
(including populations thereof), and antibodies (including antigen binding
portions
thereof), all of which are collectively referred to as "inventive TCR
materials"
hereinafter, can be formulated into a composition, such as a pharmaceutical
composition. In this regard, the invention provides a pharmaceutical
composition
comprising any of the antigen recognizing constructs, TCRs, polypeptides,
proteins,
functional portions, functional variants, nucleic acids, expression vectors,
host cells
CA 03056493 2019-09-13
WO 2018/172533 - 29 - PCT/EP2018/057482
(including populations thereof), and antibodies (including antigen binding
portions
thereof) described herein, and a pharmaceutically acceptable carrier,
excipient and/or
stabilizer. The inventive pharmaceutical compositions containing any of the
inventive
TCR materials can comprise more than one inventive TCR material, e.g., a
polypeptide
and a nucleic acid, or two or more different TCRs (including functional
portions and
functional variants thereof). Alternatively, the pharmaceutical composition
can
comprise an inventive TCR material in combination with another
pharmaceutically
active agent(s) or drug(s), such as chemotherapeutic agents, e.g.,
asparaginase,
busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil,
gemcitabine,
hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine,
etc.
Preferably, the carrier is a pharmaceutically acceptable carrier. With respect
to
pharmaceutical compositions, the carrier can be any of those conventionally
used for
the particular inventive TCR material under consideration. Such
pharmaceutically
acceptable carriers are well-known to those skilled in the art and are readily
available
to the public. It is preferred that the pharmaceutically acceptable carrier be
one, which
has no detrimental side effects or toxicity under the conditions of use.
Thus, also provided is a pharmaceutical composition, comprising any of the
herein
described products of the invention and TCR materials of the invention,
specifically any
proteins, nucleic acids or host cells. In a preferred embodiment, the
pharmaceutical
composition is for immune therapy, preferably adoptive cell therapy.
Preferably, the inventive TCR material is administered by injection, e.g.,
intravenously.
When the inventive TCR material is a host cell expressing the inventive TCR
(or
functional variant thereof), the pharmaceutically acceptable carrier for the
cells for
injection may include any isotonic carrier such as, for example, normal saline
(about
0.90% w/v of NaCI in water, about 300 mOsm/L NaCI in water, or about 9.0 g
NaCI per
liter of water), NORMOSOL R electrolyte solution (Abbott, Chicago, IL), PLASMA-
LYTE A (Baxter, Deerfield, IL), about 5% dextrose in water, or Ringer's
lactate. In an
embodiment, the pharmaceutically acceptable carrier is supplemented with human
serum albumen.
For purposes of the invention, the amount or dose (e.g., numbers of cells when
the
inventive TCR material is one or more cells) of the inventive TCR material
CA 03056493 2019-09-13
WO 2018/172533 - 30 - PCT/EP2018/057482
administered may be sufficient to affect, e.g., a therapeutic or prophylactic
response, in
the subject or animal over a reasonable time frame. For example, the dose of
the
inventive TCR material should be sufficient to bind to a cancer antigen, or
detect, treat
or prevent cancer in a period of from about 2 hours or longer, e.g., 12 to 24
or more
hours, from the time of administration. In certain embodiments, the time
period could
be even longer. The dose will be determined by the efficacy of the particular
inventive
TCR material and the condition of the animal (e.g., human), as well as the
body weight
of the animal (e.g., human) to be treated.
It is contemplated that the inventive pharmaceutical compositions, antigen
recognizing
constructs, TCRs (including functional variants thereof), polypeptides,
proteins, nucleic
acids, recombinant expression vectors, host cells, or populations of cells can
be used
in methods of treating or preventing cancer, or TAA-positive premalignancy.
The
inventive TCRs (and functional variants thereof) are believed to bind
specifically to the
TAA of the invention, such that the TCR (or related inventive polypeptide or
protein and
functional variants thereof), when expressed by or on a cell, such as a T
cell, is able to
mediate an immune response against a target cell expressing the TAA of the
invention,
preferably presenting TAA peptides via MHC I or II on the surface of said
target cell. In
this regard, the invention provides a method of treating or preventing a
condition, in
particular cancer, in a mammal, comprising administering to the mammal any of
the
pharmaceutical compositions, antigen recognizing constructs, in particular
TCRs (and
functional variants thereof), polypeptides, or proteins described herein, any
nucleic acid
or recombinant expression vector comprising a nucleotide sequence encoding any
of
the TCRs (and functional variants thereof), polypeptides, proteins described
herein, or
any host cell or population of cells comprising a nucleic acid or recombinant
vector,
which encodes any of the constructs of the invention (and functional variants
thereof),
polypeptides, or proteins described herein, in an amount effective to treat or
prevent
the condition in the mammal, wherein the condition is preferably cancer, such
as a
cancer expressing the TAA of the invention.
Examples of pharmaceutically acceptable carriers or diluents useful in the
present
invention include stabilizers such as SPGA, carbohydrates (e.g. sorbitol,
mannitol,
starch, sucrose, glucose, dextran), proteins such as albumin or casein,
protein
containing agents such as bovine serum or skimmed milk and buffers (e.g.
phosphate
CA 03056493 2019-09-13
WO 2018/172533 - 31 - PCT/EP2018/057482
buffer).
The terms "treat," and "prevent" as well as words stemming therefrom, as used
herein,
do not necessarily imply 100% or complete treatment or prevention. Rather,
there are
varying degrees of treatment or prevention of which one of ordinary skill in
the art
recognizes as having a potential benefit or therapeutic effect. In this
respect, the
inventive methods can provide any amount of any level of treatment or
prevention of a
condition in a mammal. Furthermore, the treatment or prevention provided by
the
inventive method can include treatment or prevention of one or more conditions
or
symptoms of the condition, e.g., cancer, being treated or prevented. For
example,
treatment or prevention can include promoting the regression of a tumor. Also,
for
purposes herein, "prevention" can encompass delaying the onset of the
condition, or a
symptom or condition thereof.
The present invention also relates to a method of treating cancer comprising
administering a TCR, a nucleic acid, or a host cell of the present description
in
combination with at least one chemotherapeutic agent and/or radiation therapy.
Another aspect of the invention further pertains to a method for detecting a
TAA
protein, or a complex of MHC and the TAA protein (protein epitope of the TAA),
in a
(biological) sample ¨ such as one obtained from a subject or patient
comprising
contacting the sample with an antigen recognizing construct specifically
binding to said
TAA peptide, or to the TAA peptide/MHC complex, and detecting the binding
between
said antigen recognizing construct and said TAA peptide, or to the TAA
peptide/MHC
complex. In some embodiments, the antigen recognizing construct is a TCR or
antibody, or similar constructs, or preferably the antigen recognizing
construct
according to the herein described invention. In some embodiments, the
(biological)
sample is a sample of a tumor or a cancer (such as one of those described
elsewhere
herein) for example a sample comprising tumor or cancer cells.
Also provided is a method of treating cancer in a subject in need thereof,
comprising:
a) isolating a cell from said subject;
b) transforming the cell with at least one vector encoding an antigen
recognizing
construct of the present invention to produce a transformed cell;
CA 03056493 2019-09-13
WO 2018/172533 - 32 - PCT/EP2018/057482
C) expanding the transformed cell to produce a plurality of transformed
cells; and
d) administering the plurality of transformed cells to said subject.
Also provided is a method of treating cancer in a subject in need thereof,
comprising:
a) isolating a cell from a healthy donor;
b) transforming the cell with a vector encoding an antigen recognizing
construct of
the present invention to produce a transformed cell;
c) expanding the transformed cell to produce a plurality of transformed
cells; and
d) administering the plurality of transformed cells to said subject.
Also provided is a method of detecting cancer in a biological sample
comprising:
a) contacting the biological sample with an antigen recognizing construct
of the
present description;
b) detecting binding of the antigen recognizing construct to the biological
sample.
In some embodiments, the method of detecting cancer is carried out in vitro,
in vivo or
in situ.
Also provided is a method of detecting the presence of a condition in a
mammal. The
method comprises (i) contacting a sample comprising one or more cells from the
mammal with any of the inventive TCRs (and functional variants thereof),
polypeptides,
proteins, nucleic acids, recombinant expression vectors, host cells,
populations of cells,
antibodies, or antigen binding portions thereof, or pharmaceutical
compositions
described herein, thereby forming a complex, and detecting the complex,
wherein
detection of the complex is indicative of the presence of the condition in the
mammal,
wherein the condition is cancer, such as a TAA expressing malignancy.
With respect to the inventive method of detecting a condition in a mammal, the
sample
of cells can be a sample comprising whole cells, lysates thereof, or a
fraction of the
whole cell lysates, e.g., a nuclear or cytoplasmic fraction, a whole protein
fraction, or a
nucleic acid fraction.
For purposes of the inventive detection method, the contacting can take place
in vitro
or in vivo with respect to the mammal. Preferably, the contacting is in vitro.
CA 03056493 2019-09-13
WO 2018/172533 - 33 - PCT/EP2018/057482
Also, detection of the complex can occur through any number of ways known in
the art.
For instance, the inventive antigen recognizing constructs (and functional
variants
thereof), polypeptides, proteins, nucleic acids, recombinant expression
vectors, host
cells, populations of cells, or antibodies or TCRs, or antigen binding
portions thereof,
described herein, can be labeled with a detectable label such as, for
instance, a
radioisotope, a fluorophore (e.g., fluorescein isothiocyanate (FITC),
phycoerythrin
(PE)), an enzyme (e.g., alkaline phosphatase, horseradish peroxidase), and
element
particles (e.g., gold particles).
For purposes of the inventive methods, wherein host cells or populations of
cells are
administered, the cells can be cells that are allogeneic or autologous to the
mammal.
Preferably, the cells are autologous to the mammal.
With respect to the above mentioned medical applications of the TCR material
of the
invention, the to be treated and/or diagnosed cancer can be any cancer,
including any
of acute lymphocytic cancer, acute myeloid leukemia, alveolar
rhabdomyosarcoma,
bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or
anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of
the joints,
cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity,
or middle
ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva,
chronic
lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer,
cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma,
hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer,
malignant
mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin
lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis,
pancreatic
cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate
cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft
tissue
cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the
uterus, ureter
cancer, and urinary bladder cancer. A preferred cancer is cancer is cancer of
the
uterine cervix, oropharynx, anus, anal canal, anorectum, vagina, vulva, or
penis. A
particularly preferred cancer is a TAA positive cancer, such as a FRAME
expressing
cancer, for example ovarian carcinoma, melanoma or leukemia.
CA 03056493 2019-09-13
WO 2018/172533 - 34 - PCT/EP2018/057482
In general, the invention provides a method for treating a subject suffering
from a tumor
or tumor disease comprising the administration of the antigen recognizing
constructs,
nucleic acids, vectors, pharmaceutical compositions and/or host cell as
disclosed by
the present invention. Preferably the subject is a subject in need of such a
treatment.
The subject in preferred embodiments is a mammalian subject, preferably a
human
patient, suffering from a tumor or tumor disease, which is TAA-positive.
In view of the disclosure herein it will be appreciated that the invention
furthermore
pertains to the following items:
Item 1: An antigen recognizing construct comprising at least one complementary
determining region (CDR) 3 having at least 50% sequence identity to an amino
acid
sequence selected from SEQ ID NOs. 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63,
69, 75,
81, 129, and 135.
Item 2: The antigen recognizing construct according to item 1, wherein said
antigen
recognizing construct is capable of specifically and/or selectively binding to
a TAA of
the invention antigenic peptide.
Item 3: The antigen recognizing construct according to item 1 or 2, wherein
the antigen
recognizing construct is an antibody, or derivative or fragment thereof, or a
T cell
receptor (TCR), or a derivative or fragment thereof.
Item 4: The antigen recognizing construct according to any one of items 1 to
3, wherein
said antigen recognizing construct binds to a human leucocyte antigen (HLA)
presented TAA antigenic peptide, wherein said HLA is optionally type A2.
Item 5: The antigen recognizing construct according to any one of items 1 to
4, wherein
the construct specifically and/or selectively binds to an epitope having the
amino acid
sequence selected from SEQ ID NO: 97 ¨ 115, preferably SEQ ID NO: 97.
Item 6: The antigen recognizing construct according to any one of items 1 to
5, wherein
the construct is an a/13-TCR, or fragment or derivative thereof, or the
construct is a y/6-
TCR, or a fragment or derivative thereof.
CA 03056493 2019-09-13
WO 2018/172533 - 35 - PCT/EP2018/057482
Item 7: The antigen recognizing construct according to any one of items 1 to
6,
characterized in that the construct is of human origin and specifically and/or
selectively
recognizes a TAA antigenic peptide.
Item 8: The antigen recognizing construct according to any one of items 1 to
7, wherein
said antigen recognizing construct is capable of inducing an immune response
in a
subject, optionally wherein the immune response is characterized by an
increase in
interferon (IFN) y levels.
Item 9: The antigen recognizing construct according to any one of items 1 to
8,
comprising a TCR a or y chain; and/or a TCR [3 or 6 chain; wherein the TCR a
or y
chain comprises a CDR3 having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%,
or 100% sequence identity to an amino acid sequence selected from SEQ ID Nos.
3,
15, 27, 39, 51, 63, 75, and 129, and/or wherein the TCR [3 or 6 chain
comprises a
CDR3 having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence
identity to an amino acid sequence selected from SEQ ID Nos. 9, 21, 33, 45,
57, 69,
81, and 135.
Item 10: The antigen recognizing construct according to item 9, wherein the
TCR a or y
chain further comprises a CDR1 having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%, 99%, or 100% sequence identity to an amino acid sequence selected from
SEQ
ID Nos. 1, 13, 25, 37, 49, 61, 73, and 127; and/or a CDR2 having at least 50%,
60%,
70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an amino acid
sequence selected from SEQ ID Nos. 2, 14, 26, 38, 50, 62, 74, 128, 196, 197,
198,
199, 200, 201, 202, and 204.
Item 11: The antigen recognizing construct according to item 9 or 10, wherein
the TCR
13. or 6 chain further comprises a CDR1 having at least 50%, 60%, 70%, 80%,
90%,
95%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected
from
SEQ ID Nos. 7, 19, 31, 43, 55, 67, and 79, and 133; and/or a CDR2 having at
least
50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 100% sequence identity to an amino
acid sequence selected from SEQ ID Nos. 8, 20, 32, 44, 56, 68, and 80, and
134.
CA 03056493 2019-09-13
WO 2018/172533 - 36 - PCT/EP2018/057482
Item 12: The antigen recognizing construct according to any one of items 1 to
11,
comprising a TCR variable chain region having at least 50%, 60%, 70%, 80%,
90%,
95%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected
from
SEQ ID Nos. 4, 10, 16, 22, 28, 34, 40, 46, 52, 58, 64, 70, 76, 82, 130, and
136.
Item 13: The antigen recognizing construct according to any one of items 1 to
12,
wherein the construct is humanized, chimerized and/or murinized.
Item 14: The antigen recognizing construct according to any one of items 1 to
13,
comprising a binding fragment of a TCR, and wherein said binding fragment
comprises
CDR1 to CDR3 optionally selected from the CDR1 to CDR3 sequences having the
amino acid sequences of SEQ ID Nos. 1, 2, 3, 196; or 7, 8, 9; or 13, 14, 15,
197; or 19,
20, 21; or 25, 26, 27, 198; or 31, 32, 33; or 37, 38, 39, 199; or 43, 44, 45;
or 49, 50, 51,
200; or 55, 56, 57; or 61, 62, 63, 201; or 67, 68, 69; or 73, 74, 75, 202; or
79, 80,81; or
127, 128, 129, 204; or 133, 134, 135.
Item 15: The antigen recognizing construct according to any one of items 1 to
14,
wherein the construct is a TCR, or a fragment thereof, composed of at least
one TCR a
and one TCR [3 chain sequence, wherein said TCR a chain sequence comprises the
CDR1 to CDR3 sequences having the amino acid sequences of SEQ ID NO: 1 to 3
and 196, and said TCR [3 chain sequence comprises the CDR1 to CDR3 sequences
having the amino acid sequences of SEQ ID NO: 7 to 9; or wherein said TCR a
chain
sequence comprises the CDR1 to CDR3 sequences having the amino acid sequences
of SEQ ID NO: 13 to 15 and 197, and said TCR [3 chain sequence comprises the
CDR1
to CDR3 sequences having the amino acid sequences of SEQ ID NO: 19 to 21; or
wherein said TCR a chain sequence comprises the CDR1 to CDR3 sequences having
the amino acid sequences of SEQ ID NO: 25 to 27 and 198, and said TCR [3 chain
sequence comprises the CDR1 to CDR3 sequences having the amino acid sequences
of SEQ ID NO: 31 to 33; or wherein said TCR a chain sequence comprises the
CDR1
to CDR3 sequences having the amino acid sequences of SEQ ID NO: 37 to 39 and
199, and said TCR [3 chain sequence comprises the CDR1 to CDR3 sequences
having
the amino acid sequences of SEQ ID NO: 43 to 45; or wherein said TCR a chain
sequence comprises the CDR1 to CDR3 sequences having the amino acid sequences
of SEQ ID NO: 49 to 51 and 200, and said TCR [3 chain sequence comprises the
CA 03056493 2019-09-13
WO 2018/172533 - 37 - PCT/EP2018/057482
CDR1 to CDR3 sequences having the amino acid sequences of SEQ ID NO: 55 to 57;
or wherein said TCR a chain sequence comprises the CDR1 to CDR3 sequences
having the amino acid sequences of SEQ ID NO: 61 to 63 and 201, and said TCR
13
chain sequence comprises the CDR1 to CDR3 sequences having the amino acid
sequences of SEQ ID NO: 67 to 69; or wherein said TCR a chain sequence
comprises
the CDR1 to CDR3 sequences having the amino acid sequences of SEQ ID NO: 73 to
75 and 202, and said TCR [3 chain sequence comprises the CDR1 to CDR3
sequences
having the amino acid sequences of SEQ ID NO: 79 to 81; or wherein said TCR a
chain sequence comprises the CDR1 to CDR3 sequences having the amino acid
sequences of SEQ ID NO: 127 to 129 and 204, and said TCR [3 chain sequence
comprises the CDR1 to CDR3 sequences having the amino acid sequences of SEQ ID
NO: 133 to 135.
Item 16: The antigen recognizing construct according to any one of items 1 to
15,
wherein the construct is a TCR, or a fragment thereof, comprising at least one
TCR a
and one TCR [3 chain sequence, wherein said TCR a chain sequence comprises a
variable region sequence having the amino acid sequence of SEQ ID No. 4, and
wherein said TCR [3 chain sequence comprises a variable region sequence having
the
amino acid sequence of SEQ ID No. 10; or wherein said TCR a chain sequence
comprises a variable region sequence having the amino acid sequence of SEQ ID
No.
16, and wherein said TCR [3 chain sequence comprises a variable region
sequence
having the amino acid sequence of SEQ ID No. 22; or wherein said TCR a chain
sequence comprises a variable region sequence having the amino acid sequence
of
SEQ ID No. 28, and wherein said TCR [3 chain sequence comprises a variable
region
sequence having the amino acid sequence of SEQ ID No. 34; or wherein said TCR
a
chain sequence comprises a variable region sequence having the amino acid
sequence of SEQ ID No. 40, and wherein said TCR 8 chain sequence comprises a
variable region sequence having the amino acid sequence of SEQ ID No. 46; or
wherein said TCR a chain sequence comprises a variable region sequence having
the
amino acid sequence of SEQ ID No. 52, and wherein said TCR [3 chain sequence
comprises a variable region sequence having the amino acid sequence of SEQ ID
No.
58; or wherein said TCR a chain sequence comprises a variable region sequence
having the amino acid sequence of SEQ ID No. 64, and wherein said TCR 13.
chain
sequence comprises a variable region sequence having the amino acid sequence
of
CA 03056493 2019-09-13
WO 2018/172533 - 38 - PCT/EP2018/057482
SEQ ID No. 70; or wherein said TCR a chain sequence comprises a variable
region
sequence having the amino acid sequence of SEQ ID No. 76, and wherein said TCR
[3
chain sequence comprises a variable region sequence having the amino acid
sequence of SEQ ID No. 82; or wherein said TCR a chain sequence comprises a
variable region sequence having the amino acid sequence of SEQ ID No. 130, and
wherein said TCR [3 chain sequence comprises a variable region sequence having
the
amino acid sequence of SEQ ID No. 136.
Item 17: The antigen recognizing construct according to any one of items 1 to
16,
wherein the construct is a TCR, or a fragment thereof, further comprising a
TCR
constant region having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100%
sequence identity to an amino acid sequence selected from SEQ ID Nos. 5, 11,
17, 23,
29, 35, 41, 47, 53, 59, 65, 71, 77, 83, 131, and 137, preferably wherein the
TCR is
composed of at least one TCR a and one TCR [3 chain sequence, wherein the TCR
a
chain sequence comprises a constant region having at least 50%, 60%, 70%, 80%,
90%, 95%, 98%, 99%, or 100% sequence identity to an amino acid sequence
selected
from SEQ ID Nos. 5, 17, 29, 41, 53, 65, 77, and 131; and wherein the TCR [3
chain
sequence comprises a constant region having at least 50%, 60%, 70%, 80%, 90%,
95%, 98%, 99%, or 100% sequence identity to an amino acid sequence selected
from
SEQ ID Nos. 11, 23, 35, 47, 59, 71, 83, and 137.
Item 18: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 6, and
a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 12.
Item 19: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 18,
and a
second TCR chain having at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 24.
Item 20a: The antigen recognizing construct according to any one of items 1 to
17,
CA 03056493 2019-09-13
WO 2018/172533 - 39 - PCT/EP2018/057482
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 30,
and a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 36.
Item 20b: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 42,
and a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 48.
Item 20c: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 54,
and a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 60.
Item 20d: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No.66, and
a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 72.
Item 20e: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 78,
and a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 84.
Item 20f: The antigen recognizing construct according to any one of items 1 to
17,
comprising a first TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%,
98%,
99%, or 100% sequence identity to the amino acid sequence of SEQ ID No. 132,
and a
second TCR chain haying at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or
100% sequence identity to the amino acid sequence of SEQ ID No. 138.
CA 03056493 2019-09-13
WO 2018/172533 - 40 - PCT/EP2018/057482
Item 21: A nucleic acid encoding for an antigen recognizing construct
according to any
one of items 1 to 20f.
Item 22: A vector comprising a nucleic acid according to item 21.
Item 23: A host cell comprising an antigen recognizing construct according to
any one
of items 1 to 20, or a nucleic acid according to item 21, or a vector
according to item
22.
Item 24: The host cell according to item 23, wherein the cell is a lymphocyte,
preferably
a T lymphocyte or T lymphocyte progenitor, more preferably a CD4 or CD8
positive T-
cell.
Item 25: A pharmaceutical composition comprising the antigen recognizing
construct
according to any one of items 1 to 20f, or the nucleic acid according to item
21, or the
vector according to item 22, or the host cell according to item 23 or 24, and
a
pharmaceutical acceptable carrier, stabilizer and/or excipient.
Item 26: The antigen recognizing construct according to any one of items 1 to
20f, or a
nucleic acid according to item 21, or a vector according to item 22, or a host
cell
according to item 23 or 24, or the pharmaceutical composition according to
item 25, for
use in medicine.
Item 27: The antigen recognizing construct, or the nucleic acid, or the
vector, or the
host cell, or the pharmaceutical composition, for use according to item 26,
for use in
the diagnosis, prevention, and/or treatment of a proliferative disease,
wherein the
disease comprises a malignant or benign tumor disease.
Item 28: The antigen recognizing construct, or the nucleic acid, or the
vector, or the
host cell, or the pharmaceutical composition, for use according to item 27,
wherein the
tumor disease is characterized by the expression of TAA in a tumor cell of the
tumor
disease.
CA 03056493 2019-09-13
WO 2018/172533 - 41 - PCT/EP2018/057482
Item 29: The antigen recognizing construct, or the nucleic acid, or the
vector, or the
host cell, or the pharmaceutical composition, for use according to any one of
items 26
to 28, wherein the use in medicine is a use in immune therapy optionally
comprising an
adoptive cell transfer, wherein the immune therapy comprises adoptive
autologous or
heterologous T-cell therapy.
Item 30: A method of manufacturing a TAA specific antigen recognizing
construct
expressing cell line, comprising
a., providing a suitable host cell,
b., providing a genetic construct comprising a coding sequence encoding the
antigen
recognizing construct according to any one of items 1 to 20f,
c., introducing into said suitable host cell said genetic construct,
d., expressing said genetic construct by said suitable host cell.
Item 31: The method according to item 30, further comprising cell surface
presentation
of said antigen recognizing construct.
Item 32: The method according to item 30 or 31, wherein the genetic construct
is an
expression construct comprising a promoter sequence operably linked to said
coding
sequence.
Item 33: The method according to any one of items 30 to 32, wherein said
antigen
recognizing construct is of mammalian origin, preferably of human origin.
Item 34: The method according to any one of items 30 to 33, wherein said
suitable host
cell is a mammalian cell, optionally selected from a human cell or a human T
lymphocyte.
Item 35: The method according to any one of items 30 to 34, wherein said
antigen
recognizing construct is a modified TCR, wherein said modification comprises
addition
of a functional domain comprising a label, or an alternative domain comprising
a
membrane anchor domain.
Item 36: The method according to item 35, wherein said antigen recognizing
construct
CA 03056493 2019-09-13
WO 2018/172533 - 42 - PCT/EP2018/057482
is an alpha/beta TCR, gamma/delta TCR, or a single chain TCR (scTCR).
Item 37: The method according to any one of items 30 to 36, wherein said
genetic
construct is introduced into said suitable host cell by retroviral
transfection.
Item 38: The method according to any one of items 30 to 37, further comprising
the
isolation and purification of the antigen recognizing construct from the
suitable host cell
and, optionally, reconstitution of the antigen recognizing construct in a T-
cell.
The present invention will now be further described in the following examples
with
reference to the accompanying figures and sequences, nevertheless, without
being
limited thereto. For the purposes of the present invention, all references as
cited herein
are incorporated by reference in their entireties. The Figures and Sequences
show:
Figure 1: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R11P3D3 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Several
different donors were analyzed with regard to alanine-substitution (Ala_TCRA-
0017
and Ala_IFN-041) and threonine- substitution variants (Thr_TCRA-0036).
Figure 2: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1C10 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Several
different donors were analyzed with regard to alanine-substitution (Ala_TCRA-
0017
and Ala_IFN-041) and threonine- substitution variants (Thr_TCRA-0036).
CA 03056493 2019-09-13
WO 2018/172533 - 43 - PCT/EP2018/057482
Figure 3: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1E8 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Several
different donors were analyzed with regard to alanine-substitution (Ala_TCRA-
0017
and Ala_IFN-041) and threonine- substitution variants (Thr_TCRA-0036).
Figure 4: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1A9 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- substitution
variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-106) or
control
peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained with CD8+
T-cells derived from two different healthy donors. RNA electroporated CD8+ T-
cells
alone or in co-incubation with unloaded target cells served as controls.
Different donors
were analyzed with regard to alanine-substitution variants (Ala_IFN-040 and
Ala_IFN-
041).
Figure 5: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1D7 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Different
donors were analyzed with regard to alanine-substitution (Ala_TCRA-0017 and
Ala_IFN-041) and threonine-substitution variants (Thr_TCRA-0036).
Figure 6: IFNy release from CD8+ T- cells electroporated with alpha and beta
chain
RNA of TCR R17P1G3 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
CA 03056493 2019-09-13
WO 2018/172533 -" - PCT/EP2018/057482
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T- cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Different
donors were analyzed with regard to alanine-substitution (Ala_TCRA-0017 and
Ala_IFN-041) and threonine-substitution variants (Thr_TCRA-0036).
Figure 7: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P2B6 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or various PRAME-004 alanine- or threonine-
substitution variants at positions 1-9 (X1-X9) of SEQ ID NO:97 (SEQ ID NO:98-
115) or
control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors. RNA electroporated
CD8+ T-
cells alone or in co-incubation with unloaded target cells served as controls.
Different
donors were analyzed with regard to alanine-substitution (Ala_TCRA-0017 and
Ala_IFN-041) and threonine-substitution variants (Thr_TCRA-0036).
Figure 8: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R11P3D3 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VP513B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-040
and IFN-041.
Figure 9: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1C10 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VP513B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
CA 03056493 2019-09-13
WO 2018/172533 - 45 - PCT/EP2018/057482
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from
two different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation with unloaded target cells served as controls. Different donors
were
analyzed, IFN-046 and IFN-041.
Figure 10: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1E8 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VPS13B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-040
and IFN-041.
Figure 11: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1A9 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VPS13B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-040
and IFN-041.
Figure 12: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1D7 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
CA 03056493 2019-09-13
WO 2018/172533 - 46 - PCT/EP2018/057482
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VPS13B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-040
and IFN-041.
Figure 13: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1G3 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VPS13B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-046
and IFN-041.
Figure 14: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P2B6 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) or similar but unrelated peptide TMED9-001
(SEQ ID NO:116), CAT-001 (SEQ ID NO:117), DDX60L-001 (SEQ ID NO:118),
LRRC70-001 (SEQ ID NO:119), PTPLB-001 (SEQ ID NO:120), HDAC5-001 (SEQ ID
NO:121), VPS13B-002 (SEQ ID NO:122), ZNF318-001 (SEQ ID NO:123), CCDC51-
001 (SEQ ID NO:124) or IFIT1-001 (SEQ ID NO:125) or control peptide NYES01-001
(SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells derived
from two
different healthy donors. RNA electroporated CD8+ T-cells alone or in co-
incubation
with unloaded target cells served as controls. Different donors were analyzed,
IFN-040
and IFN-041.
Figure 15: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R11P3D3 (Table 1) after co-incubation with T2 target cells loaded
with
CA 03056493 2019-09-13
WO 2018/172533 - 47 - PCT/EP2018/057482
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 16: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1C10 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
10 M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from
two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 17: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R16P1E8 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
10 M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from
two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 18: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1D7 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
10 M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from
two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 19: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P1G3 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
10 M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from
two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 20: IFNy release from CD8+ T-cells electroporated with alpha and beta
chain
RNA of TCR R17P2B6 (Table 1) after co-incubation with T2 target cells loaded
with
PRAME-004 peptide (SEQ ID NO:97) in various peptide loading concentrations
from
CA 03056493 2019-09-13
WO 2018/172533 - 48 - PCT/EP2018/057482
M to 10pM. IFNy release data were obtained with CD8+ T-cells derived from two
different healthy donors. Different donors were analyzed, TCRA-0003 and TCRA-
0017.
Figure 21: HLA-A*02/PRAME-004 tetramer or HLA-A*02/NYES01-001 tetramer
staining, respectively, of CD8+ T-cells electroporated with alpha and beta
chain RNA of
TCR R16P1C10 (Table 1). CD8+ T-cells electroporated with RNA of 1G4 TCR (SEQ
ID: 85-96) that specifically binds to the HLA-A*02/NYES01-001 complex and mock
electroporated CD8+ T-cells served as controls.
Figure 22: IFNy release from CD8+ T-cells lentivirally transduced with TCR
R11P3D3 (Table 1) (D103805 and D191451) or non-transduced cells (D103805 NT
and D191451 NT) after co-incubation with T2 target cells loaded with 100nM
PRAM E-004 peptide (SEQ ID NO:97) or similar (identical to PRAME-004 in
positions
3, 5, 6 and 7) but unrelated peptides ACPL-001 (SEQ ID NO:139), HSPB3-001 (SEQ
ID NO:140), UNC7-001 (SEQ ID NO:141), SCYL2-001 (SEQ ID NO:142), RPS2P8-
001 (SEQ ID NO:143), PCNXL3-003 (SEQ ID NO:144), AQP6-001 (SEQ ID NO:145),
PCNX-001 (SEQ ID NO:146), AQP6-002 (SEQ ID NO:147) TRGV10-001 (SEQ ID
NO:148), NECAP1-001 (SEQ ID NO:149) or FBXW2-001 (SEQ ID NO:150) or control
peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained with CD8+
T-cells derived from two different healthy donors, D103805 and D191451.
Figure 23: IFNy release from CD8+ T-cells lentivirally transduced with TCR
R11P3D3 (Table 1) after co-incubation with T2 target cells loaded with 100nM
PRAM E-004 peptide (SEQ ID NO:97) or similar (identical to PRAME-004 in
positions
3, 5, 6 and 7) but unrelated peptides (SEQ ID NO:151-195) or control peptide
NYES01-001 (SEQ ID NO:126). IFNy release data were obtained with CD8+ T-cells
derived from two different healthy donors, TCRA-0087 and TCRA-0088.
Figure 24: IFNy release from CD8+ T-cells lentivirally transduced with TCR
R11P3D3 (Table 1) (D103805 and D191451) or non-transduced cells (D103805 NT
and D191451 NT) after co-incubation with different primary cells (HCASMC
(Coronary artery smooth muscle cells), HTSMC (Tracheal smooth muscle cells),
HRCEpC (Renal cortical epithelial cells), HCM (Cardiomyocytes), HCMEC (Cardiac
microvascular endothelial cells), HSAEpC (Small airway epithelial cells), HCF
CA 03056493 2019-09-13
WO 2018/172533 - 49 - PCT/EP2018/057482
(Cardiac fibroblasts)) and iPSC-derived cell types (HN (Neurons), iHCM
(Cardiomyocytes), HH (Hepatocytes), HA (astrocytes)). Tumor cell lines UACC-
257
(PRAME-004 high), Hs695T (PRAME-004 medium), U266B1 (PRAME-004 very low)
and MCF-7 (no PRAME-004) present different amounts of PRAME-004 per cells. T-
cells alone served as controls. IFNy release data were obtained with CD8+ T-
cells
derived from two different healthy donors, D103805 and D191451.
Figure 25: IFNy release from CD8+ T-cells lentivirally transduced with TCR
R11P3D3 (Table 1) after co-incubation with different primary cells (NHEK
(Epidermal
keratinocytes), HBEpC (Bronchial epithelial cells), HDMEC (Dermal
microvascular
endothelial cells), HCAEC (Coronary artery endothelial cells), HAoEC (Aortic
endothelial cells), HPASMC (Pulmonary artery smooth muscle cells), HAoSMC
(Aortic smooth muscle cells), HPF (Pulmonary fibroblasts), SkMC (Skeletal
muscle
cells), HOB (osteoblasts), HCH (Chondrocytes), HWP (White preadipocytes), hMSC-
BM (Mesenchymal stem cells), NHDF (Dermal fibroblasts). Tumor cell lines UACC-
257 (PRAME-004 high), Hs695T (PRAME-004 medium), U266B1 (PRAME-004 very
low) and MCF-7 (no PRAME-004) present different copies of PRAME-004 per cells.
T-cells alone served as controls. IFNy release data were obtained with CD8+ T-
cells
derived from two different healthy donors, TCRA-0084 and TCRA-0085.
Figure 26: IFNy release from CD8+ T-cells lentivirally transduced with
enhanced
TCR R11P3D3 KE (Table 1) (D103805 and D191451) or non-transduced cells
(D103805 NT and D191451 NT) after co-incubation with T2 target cells loaded
with
100nM PRAME-004 peptide (SEQ ID NO:97) or similar (identical to PRAME-004 in
positions 3, 5, 6 and 7) but unrelated peptide ACPL-001 (SEQ ID NO:139), HSPB3-
001 (SEQ ID NO:140), UNC7-001 (SEQ ID NO:141), SCYL2-001 (SEQ ID NO:142),
RPS2P8-001 (SEQ ID NO:143), PCNXL3-003 (SEQ ID NO:144), AQP6-001 (SEQ ID
NO:145), PCNX-001 (SEQ ID NO:146), AQP6-002 (SEQ ID NO:147), TRGV10-001
(SEQ ID NO:148), NECAP1-001 (SEQ ID NO:149) or FBXW2-001 (SEQ ID NO:150)
or control peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained
with CD8+ T-cells derived from two different healthy donors, D103805 and
D191451.
Figure 27: IFNy release from CD8+ T-cells lentivirally transduced with
enhanced
TCR R11P3D3 KE (Table 1) after co-incubation with T2 target cells loaded with
CA 03056493 2019-09-13
WO 2018/172533 - 50 - PCT/EP2018/057482
100nM PRAME-004 peptide (SEQ ID NO:97) or similar (identical to PRAME-004 in
positions 3, 5, 6 and 7) but unrelated peptides (SEQ ID NO:151-195) or control
peptide NYES01-001 (SEQ ID NO:126). IFNy release data were obtained with CD8+
T-cells derived from two different healthy donors, TCRA-0087 and TCRA-0088.
Figure 28: IFNy release from CD8+ T-cells lentivirally transduced with
enhanced
TCR R11P3D3 KE (Table 1) (D103805 and D191451) or non-transduced cells
(D103805 NT and D191451 NT) after co-incubation with different primary cells
(HCASMC (Coronary artery smooth muscle cells), HTSMC (Tracheal smooth muscle
cells), HRCEpC (Renal cortical epithelial cells), HCM (Cardiomyocytes), HCMEC
(Cardiac microvascular endothelial cells), HSAEpC (Small airway epithelial
cells),
HCF (Cardiac fibroblasts)) and iPSC-derived cell types (HN (Neurons), iHCM
(Cardiomyocytes), HH (Hepatocytes), HA (astrocytes)). Tumor cell lines UACC-
257
(PRAME-004 high), Hs695T (PRAME-004 medium), U266B1 (PRAME-004 very low)
and MCF-7 (no PRAME-004) present different amounts of PRAME-004 per cells. T-
cells alone served as controls. IFNy release data were obtained with CD8+ T-
cells
derived from two different healthy donors, D103805 and D191451.
Figure 29: IFNy release from CD8+ T-cells lentivirally transduced with
enhanced
TCR R11P3D3 KE (Table 1) after co-incubation with different primary cells
(NHEK
(Epidermal keratinocytes), HBEpC (Bronchial epithelial cells), HDMEC (Dermal
microvascular endothelial cells), HCAEC (Coronary artery endothelial cells),
HAoEC
(Aortic endothelial cells), HPASMC (Pulmonary artery smooth muscle cells),
HAoSMC (Aortic smooth muscle cells), HPF (Pulmonary fibroblasts), SkMC
(Skeletal
muscle cells), HOB (osteoblasts), HCH (Chondrocytes), HWP (White
preadipocytes),
hMSC-BM (Mesenchymal stem cells), NHDF (Dermal fibroblasts). Tumor cell lines
UACC-257 (PRAME-004 high), Hs695T (PRAME-004 medium), U266B1 (PRAME-
004 very low) and MCF-7 (no PRAME-004) present different copies of PRAME-004
per cells. T-cells alone served as controls. IFNy release data were obtained
with
CD8+ T-cells derived from two different healthy donors, TCRA-0084 and TCRA-
0085.
Figure 30: IFNy release from CD8+ T-cells lentivirally transduced with TCR
R11P3D3 or enhanced TCR R11P3D3 KE (Table 1) or non-transduced cells after
CA 03056493 2019-09-13
WO 2018/172533 - 51 - PCT/EP2018/057482
co-incubation with tumor cell lines UACC-257 (PRAME-004 high), Hs695T (FRAME-
004 medium), U266B1 (PRAME-004 very low) and MCF-7 (no PRAME-004) present
different amounts of PRAME-004 per cells. T-cells alone served as controls.
IFNy
release of both TCRs correlates with PRAME-004 presentation and R11P3D3_KE
induces higher responses compared to R11P3D3.
Figure 31: IFNy release from CD8+ T-cells lentivirally transduced with
enhanced
TCR R11P3D3 KE (Table 1) cells after co-incubation with T2 target cells loaded
with
various PRAME-004 alanine-substitution variants at positions 1-9 (A1-A9) of
SEQ ID
NO:97 (SEQ ID NO:98-106). IFNy release data were obtained with CD8+ T-cells
derived from three different healthy donors.
Figure 32: Potency assay evaluating cytolytic activity of lentivirally
transduced T
cells expressing TCR R11P3D3 or enhanced TCR R11P3D3_KE against FRAME-
004+ tumor cells. Cytotoxic response of R11P3D3 and R11P3D3_KE transduced and
non-transduced (NT) T cells measured against A-375 (PRAME-004 low) or U2OS
(PRAME-004 medium) tumor cells. The assays were performed in a 72-hour
fluorescence microscopy-based cytotoxicity assay. Results are shown as fold
tumor
growth over time.
-
Table 1: TCR sequences of the invention
SE TCR Chain Region Sequence
0
Q ID
w
=
NO:
oe
-4
w
1 R11 P3D3 alpha CDR1 SSNFYA
u,
(44
(44
2 R11 P3D3 alpha CDR2 MTL
3 R11 P3D3 alpha CDR3 CALYNNNDMRF
4 R11 P3D3 alpha variable
MEKNPLAAPLLILWFHLDCVSSILNVEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWYRWETAKSPEAL
domain FVMTLNGDEKKKGRISATLNTKEGYSYLYIKGSQPEDSATYLCALYNNNDMRFGAGTRLTVKP
P
R11 P3D3 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
0
0
domain SDFACANAFNNS I
IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
0
,
' ,
6 R11 P3D3 alpha full-
MEKNPLAAPLLILWFHLDCVSSILNVEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWYRWETAKSPEAL
0
-
,
,
length
FVMTLNGDEKKKGRISATLNTKEGYSYLYIKGSQPEDSATYLCALYNNNDMRFGAGTRLTVKPNIQNPD
PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACA
NAFNNS I IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
7 R11 P3D3 beta CDR1 SGHNS
oo
8 R11 P3D3 beta CDR2 FNNNVP
n
1-i
m
9 R11 P3D3 beta CDR3 CASSPGSTDTQYF
oo
w
'
oe
R11 P3D3 beta variable
MDSWTFCCVSLCILVAKHTDAGVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRQTMMRGLELLIYFN
,,,=-
domain NNVPIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASSPGSTDTQYFGPGTRLTVL
.12
oe
w
11 R11P3D3 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE g
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
t..)
o
oe
12 R11P3D3 beta full-
MDSWTFCCVSLCILVAKHTDAGVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRQTMMRGLELLIYFN
-4
t..)
length NNVPIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASSPGSTDTQYFGPGTRLTVLEDLKNV
u,
(...)
FPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRY
(...)
CLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQ
GVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
13 R16P1010 alpha CDR1 DRGSQS
14 R16P1010 alpha CDR2 IY
P
15 R16P1010 alpha CDR3 CAAVISNFGNEKLTF
c,
0
16 R16P1010 alpha variable
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI
domain MFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAAVISNFGNEKLTFGTGTRLTI IP
.
,
,
0
' 17 R16P1010 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
,
domain SDFACANAFNNS I
IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
18 R16P1010 alpha full- MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVP
EGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI
length
MFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAAVISNFGNEKLTFGTGTRLTIIPNIQNP
DPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFAC
ANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
oo
n
1-i
m
oo
19 R16P1010 beta CDR1 SGHRS
t..)
o
oe
O-
20 R16P1010 beta CDR2 YFSETQ
u,
-4
4,.
oe
t..)
21 R16P1010 beta CDR3 CASSPWDSPNEQYF
22 R16P1010 beta variable
MGSRLLCWVLLCLLGAGPVKAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEY
domain FSETQRNKGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSPWDSPNEQYFGPGTRLTVT
0
23 R16P1010 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE , --
-e
-4
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
t..)
u,
(...)
(...)
24 R16P1010 beta full-
MGSRLLCWVLLCLLGAGPVKAGVTQTPRYLIKTRGQQVTLSCSPISGHRSVSWYQQTPGQGLQFLFEY
length
FSETQRNKGNFPGRFSGRQFSNSRSEMNVSTLELGDSALYLCASSPWDSPNEQYFGPGTRLTVTEDLK
NVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDS
RYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQ
QGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
25 R16P1E8 alpha CDR1 NSAFQY
P
26 R16P1E8 alpha CDR2 TY
u, t
27 R16P1E8 alpha CDR3 CAMSEAAGNKLTF
,
,
28 R16P1E8 alpha variable
MMKSLRVLLVILWLQLSWVWSQQKEVEQDPGPLSVPEGAIVSLNCTYSNSAFQYFMWYRQYSRKGPEL ' ,
,
domain LMYTYSSGNKEDGRFTAQVDKSSKYISLFIRDSQPSDSATYLCAMSEAAGNKLTFGGGTRVLVKP
29 R16P1E8 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
domain
SDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
30 R16P1E8 alpha full-
MMKSLRVLLVILWLQLSWVWSQQKEVEQDPGPLSVPEGAIVSLNCTYSNSAFQYFMWYRQYSRKGPEL 00
length LMYTYSSGNKEDGRFTAQVDKSSKYISLFIRDSQPSDSATYLCAMSEAAGNKLTFGGGTRVLVKPNIQN
,r-1
PDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFA
4
t..)
CANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
=
oe
O-
31 R16P1E8 beta CDR1 SGHAT
u,
-4
4,.
oe
t..)
32 R16P1E8 beta CDR2 FQNNGV
33 R16P1E8 beta CDR3 CASSYTNQGEAFF
34 R16P1E8 beta variable MGTRLLCWAALCLLGAELTEAGVAQSPRYKI
IEKRQSVAFWCNPISGHATLYWYQQILGQGPKLLIQFQN (:)õ
o
domain NGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVYLCASSYTNQGEAFFGQGTRLTVV
oe
-4
35 R16P1E8 beta constant
EDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
(...)
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSV
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF
36 R16P1E8 beta full- MGTRLLCWAALCLLGAELTEAGVAQSPRYKI
IEKRQSVAFWCNPISGHATLYWYQQILGQGPKLLIQFQN
length
NGVVDDSQLPKDRFSAERLKGVDSTLKIQPAKLEDSAVYLCASSYTNQGEAFFGQGTRLTVVEDLNKVF
PPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCL
SSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVL
SATILYEILLGKATLYAVLVSALVLMAMVKRKDF
p
.
37 R17P1A9 alpha CDR1 DRGSQS
38 R17P1A9 alpha CDR2 IY
.
,
,
0
39 R17P1A9 alpha CDR3 CAVLNQAGTALIF
40 R17P1A9 alpha variable
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI
domain MSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVLNQAGTALIFGKGTTLSVSS
41 R17P1A9 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
domain SDFACANAFNNS I
IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
oo
n
1-i
42 R17P1A9 alpha full-
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI m
oo
t..)
length MSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVLNQAGTALIFGKGTTLSVSSNIQNPD
=
PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACA
g-
u,
NAFNNS I IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
-4
4.
oe
t..)
43 R17P1A9 beta CDR1 SGDLS
44 R17P1A9 beta CDR2 YYNGEE
45 R17P1A9 beta CDR3 CASSAETGPWLGNEQFF
0
t..)
o
46 R17P1A9 beta variable
MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYY ,f
domain NGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSAETGPWLGNEQFFGPGTRLTVL
-4
t..)
u,
(...)
(...)
47 R17P1A9 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
48 R17P1A9 beta full-
MGFRLLCCVAFCLLGAGPVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVYWYQQSLDQGLQFLIQYY
length
NGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSAETGPWLGNEQFFGPGTRLTVLEDL
KNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALND
SRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESY
P
QQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
49 R17P1D7 alpha CDR1 TSESDYY
c,
,
,
50 R17P1D7 alpha CDR2 QEAY
7
,
Si R17P1D7 alpha CDR3 CAYRWAQGGSEKLVF
52 R17P1D7 alpha variable
MACPGFLWALVISTCLEFSMAQTVTQSQPEMSVQEAETVTLSCTYDTSESDYYLFWYKQPPSRQMILVI
domain RQEAYKQQNATENRFSVNFQKAAKSFSLKISDSQLGDAAMYFCAYRWAQGGSEKLVFGKGTKLTVNP
53 R17P1D7 alpha constant
YIQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK .0
domain SDFACANAFNNS I
IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
m
oo
t..)
o
54 R17P1D7 alpha full-
MACPGFLWALVISTCLEFSMAQTVTQSQPEMSVQEAETVTLSCTYDTSESDYYLFWYKQPPSRQMILVI re
length RQEAYKQQNATENRFSVNFQKAAKSFSLKISDSQLGDAAMYFCAYRWAQGGSEKLVFGKGTKLTVNPY -
11
IQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKS
to'
t..)
DFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
55 R17P1D7 beta CDR1 MGHDK
56 R17P1D7 beta CDR2 SYGVNS
0
t..)
o
57 R17P1D7 beta CDR3 CATELWSSGGTGELFF
oe
-4
t..)
58 R17P1D7 beta variable
MTIRLLCYMGFYFLGAGLMEADIYQTPRYLVIGTGKKITLECSQTMGHDKMYWYQQDPGMELHLIHYSY el
(...)
domain GVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCATELWSSGGTGELFFGEGSRLTVL
59 R17P1D7 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE
SYQQGVLSATI LYE I LLG KATLYAVLVSALVLMAMVKRKDS RG
60 R17P1D7 beta full- MT I RLLCYMG FYFLGAG LM EAD IYQTPRYLVIGTG
KKITLECSQTMG H DKMYWYQQDPGM ELH LI HYSY
length GVNSTEKGDLSSESTVSRIRTEHFPLTLESARPSHTSQYLCATELWSSGGTGELFFGEGSRLTVLEDLK Q
NVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDS
0
c,
RYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQ ,
QGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
0
y
0
61 R17P1G3 alpha CDR1 DRGSQS
,
,
62 R17P1G3 alpha CDR2 IY
63 R17P1G3 alpha CDR3 CAVGPSGTYKYIF
64 R17P1G3 alpha variable
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI
domain MSIYSNGDKEDGRFTAQLNKASQYVSLLI RDSQPSDSATYLCAVGPSGTYKYI FGTGTRLKVLA
oo
n
1-i
65 R17P1G3 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK 4
domain SDFACANAFNNS II PEDTFFPSP ESSCDVKLVEKSFETDTNLNFQNLSVIGFRI
LLLKVAGFNLLMTLRLWS a'
S
oe
-a
u,
-4
4,.
oe
t..,
66 R17P1G3 alpha full-
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI
length
MSIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVGPSGTYKYIFGTGTRLKVLAN IQNPD
PAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACA 0
t..)
NAFNNS I IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
=
oe
67 R17P1G3 beta CDR1 MNHEY
-4
t..)
u,
(...)
(...)
68 R17P1G3 beta CDR2 SMNVEV
69 R17P1G3 beta CDR3 CASSPGGSGNEQFF
70 R17P1G3 beta variable
MGPQLLGYVVLCLLGAGPLEAQVTQNPRYLITVTGKKLTVTCSQNMNHEYMSWYRQDPGLGLRQIYYS
domain MNVEVTDKGDVPEGYKVSRKEKRNFPLILESPSPNQTSLYFCASSPGGSGNEQFFGPGTRLTVL
71 R17P1G3 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
P
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE
0
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
oe
,,
72 R17P1G3 beta full-
MGPQLLGYVVLCLLGAGPLEAQVTQNPRYLITVTGKKLTVTCSQNMNHEYMSWYRQDPGLGLRQIYYS ,
,
length MNVEVTDKGDVPEGYKVSRKEKRNFPLILESPSPNQTSLYFCASSPGGSGNEQFFGPGTRLTVLEDLKN
,
VFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSR
,
YCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQ
GVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
73 R17P2B6 alpha CDR1 DRGSQS
74 R17P2B6 alpha CDR2 IY
oo
n
1-i
75 R17P2B6 alpha CDR3 CAVVSGGGADGLTF
m
oo
t..)
o
76 R17P2B6 alpha variable
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI re
- a
domain MFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVVSGGGADGLTFGKGTHLIIQP
u,
-4
4.
oe
t..)
77 R17P2B6 alpha constant
YIQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
domain SDFACANAFNNS II PEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRI
LLLKVAGFNLLMTLRLWS
0
oe
78 R17P2B6 alpha full-
MKSLRVLLVILWLQLSWVWSQQKEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELI ;---
-4
length
MFIYSNGDKEDGRFTAQLNKASQYVSLLIRDSQPSDSATYLCAVVSGGGADGLTFGKGTHLIIQPYIQKP
DPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFAC
ANAFNNSI I PEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRI LLLKVAGFNLLMTLRLWSS
79 R17P2B6 beta CDR1 PRHDT
80 R17P2B6 beta CDR2 FYEKMQ
81 R17P2B6 beta CDR3 CASSLGRGGQPQHF
P
82 R17P2B6 beta variable
MLSPDLPDSAWNTRLLCHVMLCLLGAVSVAAGVIQSPRHLIKEKRETATLKCYP I P RHDTVYWYQQGPG
=,
domain QDPQFLISFYEKMQSDKGS I PDRFSAQQFSDYHSELNMSSLELGDSALYFCASSLGRGGQPQHFGDGT
RLSILc,
,
,
83 R17P2B6 beta constant
EDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
7
,
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSV
SYQQGVLSATI LYE I LLGKATLYAVLVSALVLMAMVKRKDF
84 R17P2 B6 beta full-
MLSPDLPDSAWNTRLLCHVMLCLLGAVSVAAGVIQSPRHLIKEKRETATLKCYPIPRHDTVYWYQQGPG
length QDPQFLISFYEKMQSDKGS I
PDRFSAQQFSDYHSELNMSSLELGDSALYFCASSLGRGGQPQHFGDGT
RLS I LEDLNKVFPPEVAVFEPSEAE ISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKE
QPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCG A
FTSVSYQQGVLSATI LYE I LLGKATLYAVLVSALVLMAMVKRKDF
m
oo
t..)
85 1G4 alpha CDR1 DSAIYN
oe
O-
86 1G4 alpha CDR2 IQS
u,
-4
4,.
oe
t..)
87 1G4 alpha CDR3 CAVRPTSGGSYIPTF
88 1G4 alpha variable
METLLGLLILWLQLQWVSSKQEVTQIPAALSVPEGENLVLNCSFTDSAIYNLQWFRQDPGKGLTSLLLIQS
domain SQREQTSGRLNASLDKSSGRSTLYIAASQPGDSATYLCAVRPTSGGSYIPTFGRGTSLIVHP
89 1G4 alpha constant
YIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK g
domain
SDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS 64
S
0 0
- 4
t . ,
90 1G4 alpha full-
METLLGLLILWLQLQWVSSKQEVTQIPAALSVPEGENLVLNCSFTDSAIYNLQWFRQDPGKGLTSLLLIQS el
(...)
length
SQREQTSGRLNASLDKSSGRSTLYIAASQPGDSATYLCAVRPTSGGSYIPTFGRGTSLIVHPYIQNPDPA
VYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANA
FNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
91 1G4 beta CDR1 MNHEY
92 1G4 beta CDR2 SVGAGI
P
93 1G4 beta CDR3 CASSYVGNTGELFF
0
94 1G4 beta variable
MSIGLLCCAALSLLWAGPVNAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHY E
domain SVGAGITDQGEVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASSYVGNTGELFFGEGSRLTVL
,
0
95 1G4 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
,
,
domain NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
96 1G4 beta full-
MSIGLLCCAALSLLWAGPVNAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHY
length
SVGAGITDQGEVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASSYVGNTGELFFGEGSRLTVLEDLK
NVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDS
oo
RYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQ n
1-i
QGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
m
oo
t..)
o
oe
127 R11P3D3 alpha CDR1 SSNFYA
O-
u,
KE
-4
4,.
oe
t..)
_
128 R11P3D3 alpha CDR2 MTL
KE
0
t..)
129 R11P3D3 alpha CDR3 CALYNNNDMRF
o
oe
KE
-4
t..)
u,
130 R11P3D3 alpha variable
MEKNPLAAPLLILWFHLDCVSSILNVEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWYRKETAKSPEALF
KE domain
VMTLNGDEKKKGRISATLNTKEGYSYLYIKGSQPEDSATYLCALYNNNDMRFGAGTRLTVKP
131 R11P3D3 alpha constant
NIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNK
KE domain SDFACANAFNNS I
IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWS
S
P
132 R11P3D3 alpha full-
MEKNPLAAPLLILWFHLDCVSSILNVEQSPQSLHVQEGDSTNFTCSFPSSNFYALHWYRKETAKSPEALF
2
KE length
VMTLNGDEKKKGRISATLNTKEGYSYLYIKGSQPEDSATYLCALYNNNDMRFGAGTRLTVKPNIQNPDP
AVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACAN
AFNNS I IPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
,
,
7
,
133 R11P3D3 beta CDR1 SGHNS
KE
134 R11P3D3 beta CDR2 FNNNVP
KE
oo
n
1-i
135 R11P3D3 beta CDR3 CASSPGSTDTQYF
m
oo
o
oe
136 R11P3D3 beta variable
MDSWTFCCVSLCILVAKHTDAGVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRETMMRGLELLIYFN !I,
KE domain
NNVPIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASSPGSTDTQYFGPGTRLTVL
4.
oe
t..)
0
t..)
=
oe
137 R11P3D3 beta constant
EDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPAL
KE domain
NDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSE
SYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
138 R11P3D3 beta full-
MDSWTFCCVSLCILVAKHTDAGVIQSPRHEVTEMGQEVTLRCKPISGHNSLFWYRETMMRGLELLIYFN
KE length
NNVPIDDSGMPEDRFSAKMPNASFSTLKIQPSEPRDSAVYFCASSPGSTDTQYFGPGTRLTVLEDLKNV
FPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRY
CLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQ
P
GVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
0
0
196 R11P3D3 alpha CDR2bis MTLNGDE
o, .
197 R16P1010 alpha CDR2bis IYSNGD
,
198 R16P1E8 alpha CDR2bis TYSSGN
,
,
199 R17P1A9 alpha CDR2bis IYSNGD
200 R17P1D7 alpha CDR2bis QEAYKQQ
201 R17P1G3 alpha CDR2bis IYSNGD
202 R17P2B6 alpha CDR2bis IYSNGD
203 1G4 alpha CDR2bis IQSSQRE
204 R11P3D3 alpha CDR2bis MTLNGDE
oo
n
1-i
m
oo
t..)
=
oe
O-
u,
-4
4.
oe
t..)
CA 03056493 2019-09-13
WO 2018/172533 - 63 -
PCT/EP2018/057482
Table 2: Peptide sequences of the invention
Peptide Code Sequence SEQ ID NO:
PRAME-004 SLLQHLIGL 97
PRAME-004 Al ALLQHLIGL 98
PRAME-004 A2 SALQHLIGL 99
PRAME-004 A3 SLAQHLIGL 100
PRAME-004 A4 SLLAHLIGL 101
PRAME-004 A5 SLLQALIGL 102
PRAME-004 A6 SLLQHAIGL 103
PRAME-004 A7 SLLQHLAGL 104
PRAME-004 A8 SLLQHLIAL 105
PRAME-004 A9 SLLQHLIGA 106
PRAME-004 T1 TLLQHLIGL 107
PRAME-004 T2 STLQHLIGL 108
PRAME-004 T3 SLTQHLIGL 109
PRAME-004 T4 SLLTHLIGL 110
PRAME-004 T5 SLLQTLIGL 111
PRAME-004 T6 SLLQHTIGL 112
PRAME-004 T7 SLLQHLTGL 113
PRAME-004 T8 SLLQHLITL 114
PRAME-004 T9 SLLQHLIGT 115
TMED9-001 SILQTLILV 116
CAT-001 SLIEHLQGL 117
DDX60L-001 SLIQHLEEI 118
LRRC70-001 SLLKNLIYL 119
PTPLB-001 SLLNHLPYL 120
HDAC5-001 SLLQHVLLL 121
VPS13B-002 SLLQKQIML 122
ZNF318-001 SLSQELVGV 123
CCDC51-001 SVLGALIGV 124
IFIT1-001 VLLHHQIGL 125
NYES01-001 SLLMWITQV 126
CA 03056493 2019-09-13
WO 2018/172533 - 64 -
PCT/EP2018/057482
ACPL-001 LLLVHLIPV 139
HSPB3-001 IILRHLIEI 140
UNC7-001 KILLHLIHI 141
SCYL2-001 KVLPHLIPL 142
RPS2P8-001 SALVHLIPV 143
PCNXL3-003 NALVHLIEV 144
AQP6-001 VALGHLIGI 145
PCNX-001 NALVHLIEI 146
AQP6-002 WALGHLIGI 147
TRGV10-001 QALEHLIYI 148
NECAP1-001 ISLAHLILV 149
FBXW2-001 ETLDHLISL 150
ACCSL-001 ALLSHLICR 151
ACER1-001 KELRHLIEV 152
ADAMTS14-001 IALVHLIMV 153
ARHGAP17-001 CWLCHLIKL 154
ARSE-001 GKLTHLIPV 155
ATP-009 HLLMHLIGS 156
AUNI-001 TQLDHLIPG 157
C16orf96-001 QDLWHLIKL 158
CDC7-002 IALKHLIPT 159
CDC7-003 IALKHLILT 160
CHRNA1-001 LQUHLINV 161
FASTKD5-001 SQLVHLIYV 162
FRYL-002 CLLPHLIQH 163
FTH1-001 MVLVHLIHS 164
HERC4-002 SDLFHLIGV 165
H PS5-001 KLLFHLIQS 166
H PS5-002 KLLLHLIQS 167
HTR2C-001 SFLVHLIGL 168
IPM-001 YGLKHLISV 169
KIF16-001 SELPHLIGI 170
KLHL33-001 YALSHLIHA 171
CA 03056493 2019-09-13
WO 2018/172533 - 65 - PCT/EP2018/057482
LAMA3-001 TLLGHLISK 172
L00100128170-001 SQLSHLIAM 173
MAP2K7-001 FFLVHLICM 174
MON2-003 VSLHHLINA 175
OR2AK2-001 IMLIHLIRL 176
OR2AK2-002 ITLIHLIRL 177
0R2B6-001 SELFHLIPL 178
0R2B6-002 SVLFHLIPL 179
OTUD7A-001 AQLAHLILS 180
OVOS2-001 FLLGHLIPR 181
PIGC-002 MLLGHLIFF 182
RAD54L2-003 VLLFHLIEE 183
RASEF-001 VFLRHLITL 184
RASGRF1-003 TLLDHLIFK 185
RPS2P20-001 SVLVHLIPA 186
SACS-001 AKLEHLIYL 187
SPATA31D5-001 SLLPHLILS 188
TPST2-001 SILGHLICS 189
TRGV10-002 QSLEHLIYI 190
UGP-001 YILNHLINP 191
USP51-001 YKLLHLIWI 192
ZNF423-002 KLLCHLIEH 193
ZNF584-001 ALLDHLITH 194
ZNF99-001 FMLSHLIQH 195
EXAMPLES
Seven FRAME-specific TCRs directed to the herein disclosed FRAME-004 peptide
(R11P3D3, R16P1C10, R16P1E8, R17P1A9, R17P1D7, R17P1G3 and R17P2B6, see
Table 1), each encoding tumor specific TCR-alpha and TCR-beta chains, were
isolated
and amplified from T-cells of healthy donors. Cells from healthy donors were
in vitro
stimulated according to a method previously described (Walter et al., 2003 J
Immunol.,
Nov 15;171(10):4974-8) and target-specific cells were single-cell sorted using
HLA-
A*02 multimers and then used for subsequent TCR isolation. TCR sequences were
CA 03056493 2019-09-13
WO 2018/172533 - 66 - PCT/EP2018/057482
isolated via 5' RACE by standard methods as described by e.g. Molecular
Cloning a
laboratory manual fourth edition by Green and Sambrook. The alpha and beta
variable
regions of TCRs R11P3D3, R16P1C10, R16P1E8, R17P1A9, R17P1D7, R17P1G3 and
R17P2B6 were sequenced and cloned for further functional characterization.
R11P3D3, R16P1C10, R17P1D7 and R17P2B6 are derived from HLA-A*02 negative
donor (alloreactive setting) and R16P1E8, R17P1A9 and R17P1G3 are derived from
a
HLA-A*02 positive donor.
Furthermore, the mutant TCR R11P3D3_KE, an enhanced variant of R11P3D3, is
herein disclosed. Enhanced TCR variant R11P3D3 KE was modified from the
parental
TCR as described in PCT/EP2017/081745, herewith specifically incorporated by
reference, and in example 8 below, and the coding sequence was obtained by
gene
synthesis prior to the functional characterization of the TCR.
Example 1: T-cell receptor R11P3D3
TCR R11P3D3 (SEQ ID NO:1-12 and 196) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 8).
R11P3D3 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine or threonine substitution
variants of
PRAME-004 (Figure 1) or different peptides showing high degree of sequence
similarity
to PRAME-004 (Figure 8). NYES01-001 peptide is used as negative control. TCR
R11P3D3 has an EC50 of 0.74 nM (Figure 15) and a binding affinity (KD) of 18 ¨
26 M
towards HLA-A*02-presented PRAME-004 (SEQ ID NO:97).
Re-expression of R11P3D3 in human primary CD8+ T-cells leads to selective
recognition and killing of HLA-A*02/PRAME-004-presenting tumor cell lines
(Figures 24,
25 30 and 32). TCR R11P3D3 does not respond to any of the 25 tested healthy,
primary or iPSC-derived cell types (Figures 24 and 25) and was tested for
cross-
reactivity towards further 67 similar peptides (of which 57 were identical to
FRAME-
004 in positions 3, 5, 6 and 7) but unrelated peptides in the context of HLA-
A*02
(Figures 8, 22 and 23).
CA 03056493 2019-09-13
WO 2018/172533 - 67 - PCT/EP2018/057482
Example 2: T-cell receptor R16P1 C10
TCR R16P1C10 (SEQ ID NO:13-24 and 197) is restricted towards HLA-A*02-
presented
PRAME-004 (SEQ ID NO:97) (see Figure 9).
R16P1C10 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells and
bind HLA-A*02 tetramers (Figure 21), respectively, loaded either with PRAME-
004
peptide or alanine or threonine substitution variants of PRAME-004 (Figure 2)
or
different peptides showing high degree of sequence similarity to PRAME-004
(Figure
9). NYES01-001 peptide is used as negative control. TCR R16P1C10 has an EC50
of
9.6nM (Figure 16).
Example 3: T-cell receptor R16P1E8
TCR R16P1E8 (SEQ ID NO:25-36 and 198) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 10).
R16P1E8 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine or threonine substitution
variants of
PRAME-004 (Figure 3) or different peptides showing high degree of sequence
similarity
to PRAME-004 (Figure 10). NYES01-001 peptide is used as negative control. TCR
R16P1E8 has an EC50 of -1 M (Figure 17).
Example 4: T-cell receptor R17P1A9
TCR R17P1A9 (SEQ ID NO:37-48 and 199) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 11).
R17P1A9 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine substitution variants of PRAME-
004
(Figure 4) or different peptides showing high degree of sequence similarity to
FRAME-
004 (Figure 11). NYES01-001 peptide is used as negative control.
CA 03056493 2019-09-13
WO 2018/172533 - 68 - PCT/EP2018/057482
Example 5: T-cell receptor R17P1 07
TCR R17P1D7 (SEQ ID NO:49-60 and 200) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 12).
R17P1D7 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine or threonine substitution
variants of
PRAME-004 (Figure 5) or different peptides showing high degree of sequence
similarity
to PRAME-004 (Figure 12). NYES01-001 peptide is used as negative control. TCR
R17P1D7 has an EC50 of 1.83 nM (Figure 18).
Example 6: T-cell receptor R17P1G3
TCR R17P1G3 (SEQ ID NO:61-72 and 201) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 13).
R17P1G3 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine or threonine substitution
variants of
PRAME-004 (Figure 6) or different peptides showing high degree of sequence
similarity
to PRAME-004 (Figure 13). NYES01-001 peptide is used as negative control. TCR
R17P1G3 has an EC50 of 8.63 nM (Figure 19).
Example 7: T-cell receptor R17P2B6
TCR R17P2B6 (SEQ ID NO:73-84 and 202) is restricted towards HLA-A*02-presented
PRAME-004 (SEQ ID NO:97) (see Figure 14).
R17P2B6 specifically recognizes PRAME-004, as human primary CD8+ T-cells re-
expressing this TCR release IFNy upon co-incubation with HLA-A*02+ target
cells,
loaded either with PRAME-004 peptide or alanine or threonine substitution
variants of
PRAME-004 (Figure 7) or different peptides showing high degree of sequence
similarity
to PRAME-004 (Figure 14). NYES01-001 peptide is used as negative control. TCR
R17P2B6 has an EC50 of 2.11 nM (Figure 20) and a binding affinity (KD) of 13
M
towards HLA-A*02-presented PRAME-004.
CA 03056493 2019-09-13
WO 2018/172533 - 69 - PCT/EP2018/057482
Example 8: Enhanced T-cell receptor R11P3D3_KE
The mutated "enhanced pairing" TCR R11P3D3_KE is introduced as a variant of
R11P3D3, where a and 13 variable domains, naturally bearing aW44/ 13044, have
been mutated to aK44/ 13E44. The double mutation is selected among the list
present
in PCT/EP2017/081745, herewith specifically incorporated by reference. It is
specifically designed to restore an optimal interaction and shape
complementarity to
the TCR scaffold.
Compared with the parental TCR R11P3D3 the enhanced TCR R11P3D3_KE shows
superior sensitivity of PRAME-004 recognition. The response towards PRAME-004-
presenting tumor cell lines are stronger with the enhanced TCR R11P3D3_KE
compared to the parental TCR R11P3D3 (Figure 30). Furthermore, the cytolytic
activity
of R11P3D3 KE is stronger compared to R11P3D3 (Figure 32). The observed
improved functional response of the enhanced TCR R11P3D3_KE is well in line
with an
increased binding affinity towards PRAME-004, as described in example 1
(R11P3D3,
KD .18-26 M) and example 8 (R11P3D3_KE, KD .5.3 M).
